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Abstract 
 As C-terminal inhibitors of a 90-kDa heat shock protein (Hsp90), novobiocin 
and its derivatives are a significant part of an emerging class of cancer 
chemotherapeutic agents.  Previous studies have shown that analogues of the 
coumarin and benzamide moieties of novobiocin exhibit more than a 1000-fold 
improvement in activity over the parent compound.  This thesis describes synthetic 
efforts toward the completion of noviose mimics to determine moieties that are 
critical for binding or can be altered for improved activity.  Additionally, in the 
absence of a co-crystal structure for the Hsp90 C-terminus, there is a need to develop 
an accurate model to assist in efficient drug design. This work describes the use of 
molecular modeling and docking software to design new, potentially useful models of 
C-terminal interactions. 
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Introduction and Background 
 Heat shock proteins are molecular chaperones that are upregulated in response 
to stressful cellular conditions, such as exposure to toxins, hypoxia, or elevated 
temperatures caused by inflammation or other means.  Of these, the 90-kDa heat 
shock protein, Hsp90, is an emerging target for the treatment of diseases due to its 
ability to refold denatured proteins or to fold nascent polypeptides, as well as its role 
in solubilizing protein aggregates that are often associated with neurodegenerative 
diseases.  Of particular note is the fact that Hsp90 client proteins are intertwined with 
all of the six hallmarks of cancer, as defined by Hanahan and Weinberg,1 leading to 
the hypothesis that inhibition of Hsp90 could simultaneously disrupt multiple 
pathways associated with malignancy, producing very potent and selective cancer 
chemotherapeutics.  Natural product discoveries and associated synthetic and 
biological efforts have paved the way for the significant progress that has been made 
within the past decade in this area of research, and continue to shape our 
understanding of Hsp90 and its implications as a therapeutic target.      
Geldanamycin and Derivatives. Originally discovered as an antimicrobial 
compound in 1970, geldanamycin (GDM, Fig. 1) is a member of the ansamycin 
family of antibiotics and has been shown to exhibit activity against the growth and 
development of protozoa.  The initial isolate was extracted from an actinomycete soil 
sample from Kalamazoo, Michigan. GDM was screened against a number of 
protozoae both in vitro and in vivo, and demonstrated antimicrobial activity against 
Alternizaria, Pythium, Botrytis and Penicillium.  The minimal inhibitory 
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concentration (MIC) of GDM was most notable for Tetrahymena pyriformis at 2 
mg/mL and Crithidia fasciculata at 4 mg/mL.2   
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Figure 1. Structure of geldanamycin (GDM). 
 
Upon further testing, GDM was found to possess antiproliferative activity 
against a wide range of tumor cell lines, which was believed to result from direct 
inhibition of v-Src, a tyrosine specific kinase that is involved in several signal 
transduction pathways and regulates the growth and proliferation of transformed 
cells.3 Although GDM did significantly diminish v-Src kinase activity in cells,4 it was 
inactive against the purified protein, suggesting that GDM was indirectly inhibiting v-
Src kinase activity via an alternative mechanism.5 Through affinity purification, 
Whitesell and Neckers determined that GDM was reversibly binding a protein, 
Hsp90.6 It was proposed that the Hsp90 molecular chaperone was responsible for the 
conformational maturation of v-Src and, therefore, the activity was dependent upon 
Hsp90. These researchers demonstrated that upon administration of GDM, v-Src and 
other Hsp90-dependent protein substrates were degraded in cell lysates, thereby 
linking client protein degradation to Hsp90 inhibition. Subsequent studies have 
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shown that upon Hsp90 inhibition, Hsp90-dependent client proteins become 
substrates for the ubiquitin-proteasome pathway.7  
In 1997, Stebbins and coworkers reported the first co-crystal structure of 
GDM bound to Hsp90 (Fig. 2).8 At the time, GDM was believed to bind to the client 
protein binding site. However, studies revealed that GDM bound to the N-terminal 
ATP-binding site of Hsp90, and that in the presence of GDM, the inherent ATPase 
activity of Hsp90 was diminished.9 The co-crystal structure also revealed two key 
features of GDM when bound to Hsp90. First, GDM binds Hsp90 in a bent 
conformation and contains a cis-amide bond,8 distinctive from the native crystal 
structure in which it adopts a relatively flat conformation with a trans-amide 
bond.10,11 Additionally, the quinone ring binds Hsp90 towards the surface of the 
protein, suggesting that modifications at the 17-position should not affect inhibitory 
activity.12 
 
Figure 2. Co-crystal structure of GDM bound to yeast Hsp90.12 
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In vivo studies with GDM proved to be problematic as the redox-active 
quinone and the labile nature of the 17-methoxy substituent led to hepatotoxicity.13,14 
In an effort to decrease the electron-deficient nature of the quinone ring and to 
remove the labile 17-methoxy group, researchers prepared numerous GDM 
analogues. The most potent of these was 17-(allylamino)-17-demethoxygeldanamycin 
(17-AAG, Scheme 1).15 17-AAG has demonstrated improved inhibitory activity and 
decreased hepatotoxicty compared to GDM.15,16 Consequently, 17-AAG entered 
clinical trials as the first Hsp90 inhibitor for the treatment of cancer and more recently 
advanced to Phase II trials.17,18  
 Despite improvements over GDM, 17-AAG still exhibits poor solubility in 
animal studies, suggesting that further modifications are needed to alleviate these 
undesired properties. In 2004, researchers at Kosan Biosciences reported the synthesis 
and evaluation of 17-DMAG, which exhibits significantly greater aqueous solubility 
than 17-AAG and may have potential use as an orally administered drug (Scheme 
1).19,20 In contrast to 17-AAG, 17-DMAG contains a tertiary ammonium group that is 
ionized at physiological pH. Consequently, 17-DMAG has also entered clinical trials 
and is expected to complement 17-AAG. 
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Scheme 1.  Synthesis of 17-AAG and the structure of 17-DMAG. 
 
To improve selectivity of 17-AAG and to occupy both N-terminal ATP-
binding sites of the homodimeric protein, researchers prepared GDM dimers.21 The 
four-carbon tether (Fig. 3) produced by Rosen and coworkers exhibited the greatest 
inhibitory activity for this series of compounds and demonstrated high selectivity 
toward the Her2 family of receptors. Subsequently, Kuduk and coworkers attempted 
to prepare compounds for selective inhibition of Hsp90-dependent client proteins 
such as the estrogen receptor (ER).22 After identification of the optimal tether for 
linking GDM with estradiol, these hybrids were prepared and evaluated against the 
MCF-7 human breast cancer cell line. Compared to 17-AAG, these compounds 
exhibited enhanced selectivity towards the ER and Her2, but exhibited reduced 
activity against Raf-1. Shortly thereafter, these researchers developed a GDM-
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testosterone hybrid to target the androgen receptor for potential use in prostate 
cancer.23 Results obtained from these studies suggested that these molecules may 
have therapeutic applications for advanced breast and prostate cancers, respectively. 
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Figure 3.  Structures of a GDM dimer, estradiol-GDM, and testosterone-GDM. 
 
The ability of GDM to modulate Hsp90 function makes it an ideal ligand for 
the exploitation of low affinity ligands for other therapeutic targets. For example, 
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Chiosis and colleagues prepared heterodimers of GDM and LY294002, a small-
molecule inhibitor of phosphoinositol-3 kinase (PI3K), in hopes that the bifunctional 
ligand could regulate PI3 kinase activity.  These heterodimers, with linkers varying in 
composition, length, and site of attachment showed improved efficacy and specificity 
toward the inhibition of PI3K and PI3K-related proteins.  One of the identified 
derivatives, LY6-GM (Fig. 4), exhibited a two-fold increase in selectivity for DNA-
dependent protein kinase (DNA-PK) versus PI3K.24 
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Figure 4. Structures of LY6-GM and H-GDM. 
The anti-Her2 monoclonal antibody (mAb) Herceptin has shown clinical 
efficacy for carcinomas that overexpress Her2, an Hsp90 client protein.25 In an 
attempt to improve the anticancer activity of Herceptin and other anti-Her2 mAbs, the 
GDM derivative 17-aminopropylamino-geldanamycin (17-APA-GA) was attached to 
lysine residues on the mAbs through a stable linker.26,27 The Herceptin-GDM 
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immunoconjugate (H-GDM, Fig. 4) exhibited 10–200 fold increased antiproliferative 
activity against various cancer cell lines. In addition, H-GDM treatment prolonged 
survival of xenograft-bearing mice compared to Herceptin treatment alone through 
decreased tumor growth and induced tumor regression. These results suggest that 
immunoconjugates of this type can provide a complementary approach to treat certain 
types of cancer. 
Attempts to identify structure–activity relationships for GDM have proven 
difficult. To date, few total syntheses of GDM have been reported, requiring from 20 
to more than 40 linear steps to complete.28 Researchers at Kosan Biosciences have 
taken a complementary approach toward the preparation of GDM analogues through 
modification of the GDM biosynthetic pathway to produce novel bioengineered 
geldanamycin analogues (Fig. 5).29 The most important finding from their studies was 
that KOSN1559 exhibited higher affinity for Hsp90 compared to GDM. This is 
especially significant because the phenol is not redox-active and is likely to augment 
the liability associated with the quinone compounds that are currently in clinical 
trials.  
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Figure 5. Bioengineered GDM analogues. 
 
 In addition to their uses as anti-cancer agents, GDM and its derivatives have 
been utilized to probe the mechanism by which Hsp90 inhibition regulates tumor cell 
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growth. 17-AAG has shown differential selectivity towards cancer cells and studies 
have revealed that it accumulates in malignant cells at higher concentrations than the 
surrounding media.30 However, this could not be directly correlated to Hsp90 
inhibition because 17-AAG inhibits purified Hsp90 at low micromolar 
concentrations, but manifests low nanomolar activity in tumor cell proliferation 
studies.16 Consequently, studies were needed to identify the mechanism by which 17-
AAG exhibits enhanced inhibitory activity in cells. 
 In 2003, Kamal and coworkers reported that 17-AAG exhibits higher affinity 
for the Hsp90 heteroprotein complex found in transformed cells.31 Using 
immunoprecipitation techniques, Hsp90 was isolated from several tumor cell lines 
and was shown to exist as a heteroprotein complex composed of client proteins, co-
chaperones, and partner proteins; whereas Hsp90 isolated from normal cells was 
found to reside as a homodimeric protein, uncomplexed to other proteins. The 
ATPase activities of homodimeric Hsp90 and the Hsp90 multiprotein complex were 
measured. Tumorigenic Hsp90 heteroprotein complexes were shown to have a higher 
ATPase activity than the homodimeric protein, and this increased activity correlated 
directly with its increased affinity for 17-AAG. Thus, tumor-derived Hsp90 has a 
higher affinity for N-terminal ligands than the homodimeric protein used in general 
ATPase assays.  
GDM has also been used as a molecular probe in fluorescence polarization 
(FP) assays by the incorporation of fluorescent dyes onto the 17-position of the 
quinone ring.32 These relatively small molecules tumble more slowly when bound to 
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Hsp90 than when floating freely in solution and can therefore be used to identify 
competitive inhibitors of the Hsp90 N-terminal ATP-binding site.  These FP assays 
are more useful than other methods such as isothermal calorimetry, circular 
dichroism, or even filter binding assays that use [3H]17-AAG because they do not 
require large quantities of protein or radioactive materials.33 Two novel 
geldanamycin-derived fluorescent probes were reported by Chiosis and coworkers, 
GM-FITC and GM-BODIPY, Fig. (6).32   
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Figure 6.  Structure of GM-BODIPY. 
 
Biotinylated GDM (bGDM, Fig. 7) has also been prepared and used for 
affinity purification and assay development. Introduction of a diamino group at the 
17-position of the quinone ring allowed subsequent coupling of the primary amine 
with biotin. These compounds were used to identify other proteins that bound 
bGDM.34 In addition, bGDM was used by Kamal and coworkers in competitive 
binding assays to measure binding affinities of 17-AAG for immunoprecipitated 
Hsp90 heteroprotein complexes.32 This bGDM has also been used in fluorescence 
studies by researchers at the Genomics Institute of the Novartis Research Foundation, 
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where a time-resolved fluorescence resonance energy transfer (FRET)-based high-
throughput screening assay was developed to screen a library of ~100,000 
compounds.34 Using this technique, the researchers identified several small molecules 
that exhibit binding affinities for Hsp90 in the high nanomolar range.  
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Figure 7.  Structure of biotinylated GDM. 
 
Although GDM and its derivatives have shown initial promise as cancer 
chemotherapeutics, an efficient synthetic procedure has not been developed that can 
be used to identify structure–activity relationships or improved analogues. In 
addition, the hepatotoxicity and redox-active nature of GDM derivatives represent 
major obstacles for increasing the activity for this family of compounds. 
Consequently, there remains a tremendous need to develop more efficacious 
compounds that lack these negative properties.  
Radicicol and related compounds. Like GDM, radicicol (RDC, Fig. 8) was 
also believed to be a specific v-Src kinase inhibitor prior to elucidation of Hsp90 as 
its biological target.36 The 14-membered macrolide was isolated from the culture 
broth of Monosporium bonorden in 1953 as an antifungal antibiotic.37 Subsequent 
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studies confirmed that RDC possessed the ability to suppress the transformation of 
Ras, Src and Mos oncogenes, which led to the development of RDC as an anticancer 
agent. Later studies demonstrated that this antitumor activity was based on its ability 
to bind and inhibit Hsp90 ATPase activity, which in cells resulted in the degradation 
of signaling proteins that served as nodes in oncogenic pathways.36,38 RDC was 
shown to compete with GDM for binding to the N-terminus of purified human Hsp90 
and to alter the cellular level of Hsp90-dependent client proteins in human breast 
cancer cell lines.36 These experiments confirmed that like geldanamycin, RDC exerts 
its anticancer activity through inhibition of the Hsp90 protein folding machinery. 
 RDC exhibits a higher affinity for full-length homodimeric Hsp90 than GDM 
(Kd = 19 nM and 1.2 μM, respectively) and is significantly more potent against the 
purified recombinant Hsp90 ATPase assay.12 Of note, the different Kd values 
obtained for GDM are a result of the different assays used to measure its ability to 
bind Hsp90. RDC is not redox active and does not exhibit hepatotoxicity like GDM 
and its derivatives.39 In addition, RDC has demonstrated potent cytotoxicity against 
retinoblastoma-negative cells known to be resistant to 17-AAG.40 However, RDC has 
not been shown to possess differential selectivity towards tumorigenic Hsp90 
multiprotein complexes in the same manner as GDM derivatives. The native crystal 
structure of RDC and its bound conformation are identical, suggesting that the 
relatively inflexible ring system is likely to bind both the activated and unactivated 
forms of Hsp90 with equal affinity and thus prohibit differential inhibition of the 
tumorgenic heteroprotein complex.12,41 In contrast to GDM, which exhibits an 
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entropic penalty upon Hsp90 binding due to conformational reorganization and 
isomerization of the amide bond, RDC binds Hsp90 with a favorable entropic binding 
energy resulting from the displacement of water from the ATP binding site.12  
 
Figure 8. Radicicol and various analogues. 
 
 The crystal structure of RDC bound to yeast Hsp90 shows that the resorcinol 
ring provides key binding interactions with the protein, which appear essential for its 
high affinity (Fig. 9).12 The 3-hydroxyl forms a hydrogen bond with Asp79 and a 
conserved water molecule, mimicking key interactions of the natural adenine base. 
The 5-hydroxyl forms a hydrogen bond with Leu34. The chloro substituent partially 
fills a hydrophobic cavity that is important for biological activity. In fact, monocillin, 
which lacks the chlorine atom, manifests substantially lower affinity for Hsp90 than 
RDC.  
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Figure 9. Co-crystal structure of RDC bound to yeast Hsp90.12 
 
In contrast to GDM, RDC lacks antitumor activity in vivo.42 It is thought that 
the allylic epoxide and the α,β,γ,δ-unsaturated ketone undergo nucleophilic addition 
that results in biologically inactive metabolites. It has been shown that thiol-derived 
nucleophiles inactivate RDC, presumably through this process.43 In an attempt to 
decrease the electrophilic nature of these functionalities, 6-oxime and halohydrin 
derivatives of RDC were prepared and evaluated for anticancer potential (Fig. 8).44,45 
Both KF2570644 and 9b45 were synthesized and evaluated as a mixture of both 
the E- and Z-isomers. These compounds manifested potent antiproliferative activity 
and induced the degradation of Hsp90-dependent client proteins in vitro. In addition, 
they exhibited significant activity in vivo against human tumor xenograft models. The 
most potent of these derivatives to date, 9b, demonstrated a 3–12 fold increase in 
TYR125 
TRP148 
ASP79 
ASN37 
LYS44 
ASP40 
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antiproliferative activity in various cancer cell lines and showed enhanced inhibition 
of v-Src activity compared to RDC (IC50 = 25 nM and 180 nM, respectively).45 
Purification of the E-oxime from the mixture of isomers led to identification of 
KF58333 as the biologically active inhibitor.46 In fact, KF58333 maintained potent 
inhibition of tumor growth in xenograft models, while the Z-isomer was inactive. 
This data suggests the configuration at the 6-position is important for in vivo activity 
of oxime derivatives. The bromohydrin KF23542 displayed inhibitory activity 
comparable to RDC in vitro, however, its inactivity in vivo appears to result from its 
rapid conversion to the epoxide (RDC) and subsequent metabolic inactivation.47  
Although RDC has been previously synthesized,48 recent work by 
Danishefsky and coworkers has led to a succinct synthesis of this natural product and 
identification of the first structure–activity relationships for RDC and Hsp90.40,49 
Evaluation of the inhibitory activity of RDC analogues with varying stereochemistry 
demonstrated the importance of the natural configuration for inhibitory activity. In 
order to replace the problematic allylic epoxide with a more stable isostere, a 
cyclopropyl analogue of RDC was prepared (cycloproparadicicol, c-RDC, Fig 10). 
The antiproliferative activity of c-RDC was comparable to RDC (IC50 = 43 and 23 
nM, respectively) against MCF-7 cells.40 In addition, only c-RDC with the same 
configuration as RDC demonstrated inhibitory activity. 
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                         Figure 10. Cycloproparadicicol and various analogues. 
 
Recent improvements toward the synthesis of RDC through use of the 
‘ynolide method’ provided several new c-RDC analogues for elucidation of structure–
activity relationships.50 The co-crystal structure of RDC bound to Hsp90 suggests that 
the epoxide oxygen of RDC forms a hydrogen bond with Lys58. However, 
replacement of this moiety with a methylene group (c-RDC) resulted in only a two-
fold decrease in inhibitory activity, suggesting that the conformation exerted on the 
macrocycle by the three-membered ring is more important than the hydrogen bonding 
interaction. This is further supported by the difluoro c-RDC derivative, which should 
provide complementary interactions with Lys58, however, this compound exhibited 
significantly lower activity (GI50 = 3 μM).50 In contrast to the results described above 
for the 6-oxime derivatives of RDC, the Z-oxime of c-RDC36 was 3-fold more active 
than the corresponding E-isomer.50 Conformational analysis of RDC and its 
analogues suggest that the Z-isomer is predisposed to a bioactive conformation.51 The 
in vivo inhibitory activity of these compounds has not yet been reported. 
Other compounds in the 14-membered resorcinolic macrolide class have been 
prepared and evaluated for inhibitory activity (Fig. 11). Both Aigialomycin D50 and 
des-chloro Pochonin D51 exhibit significantly decreased inhibitory activity compared 
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to RDC. Combined with the low activity demonstrated for monocillin, these data 
underline the importance of the chlorine atom for optimal inhibitory activity. Both 
Pochonin D51 and A50 are high affinity binders of Hsp90 (IC50 = 80 and 90 nM, 
respectively); however, in vitro activities for these compounds reside in the low 
micromolar range.  
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Figure 11. RDC-related macrolide Hsp90 inhibitors. 
 
Both the ynolide approach by Danishefsky and coworkers to prepare RDC 
analogues and the polymer-assisted method used by Winssinger and colleagues to 
prepare Pochonin D and related derivatives have provided a platform upon which 
future analogues can be prepared and more efficacious compounds identified. Results 
from such studies may lead to useful alternatives to the redox-active geldanamycin 
derivatives that are currently in clinical trials.  
Radicicol and geldanamycin chimeras.  As stated previously, RDC and 
GDM are the most potent natural product N-terminal inhibitors of Hsp90 identified 
thus far. However, both molecules exhibit potential liabilities as a result of their 
electrophilic properties and/or redox-active behavior. In contrast to RDC, GDM 
derivatives have been shown to possess differential selectivity that appears directly 
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related to the bent conformation of GDM bound to Hsp90, which contains an 
isomerized trans to cis amide bond.53,54 On the other hand, RDC retains the same 
conformation bound and unbound to Hsp90 and inhibits the Hsp90 homodimer 
ATPase activity at low nanomolar concentrations as compared to the low micromolar 
inhibitory activity of GDM.  
 Figure 12 shows the superimposed co-crystal structures of RDC and GDM 
bound to the N-terminus of yeast Hsp90.12 The resorcinol ring of RDC occupies the 
same region as the carbamate of geldanamycin and the purine ring of ATP. However, 
the quinone rests at the protein–solution interface, in the same region as the catalytic 
residues required for ATP hydrolysis.54 It has been proposed that these amino acids 
are involved in isomerization of the geldanamycin amide and, therefore, play a key 
role in the differential selectivity observed for this molecule. Unfortunately, only 
lengthy total syntheses of geldanamycin have been reported to date and improved 
analogues have not been published.28 Therefore, it was proposed that one could use 
the high-affinity resorcinol ring as a surrogate for the GDM carbamate to create 
molecules that contain a macrocyclic ring system that incorporated the quinone and 
amide functionalities of GDM. Radanamycin, a chimera of radicicol and 
geldanamycin, was designed in silico to determine whether this hybrid could 
complement the binding interactions of each natural product. Radamide and radester 
were prepared and evaluated as seco-agents in an effort to determine the optimal 
tethers to connect the quinone and resorcinol moieties.  
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Figure 12. Superimposed co-crystal structures of radicicol (magenta) and  
                   geldanamcyin (yellow) bound to Hsp90.12 
 
 
The first chimeric compound prepared, radamide, provided an efficient 
synthetic method through which numerous analogues could be prepared (Fig. 13).53 
Upon evaluation of radamide in the Hsp90 ATPase assay, it was found that the 
quinone-containing compound exhibited an IC50 value of 5.9 μM, which compared 
well to that of geldanamycin (2.5 μM).54 However, the quinone was not the most 
active compound. Instead, it was the hydroquinone that exhibited an IC50 value of 1.9 
μM. An analogue that contained a trimethoxy substituted ring in lieu of the quinone 
resulted in an IC50 value greater than 50 μM, suggesting that detrimental interactions 
occur in the binding pocket despite its close proximity to the aqueous solution. The 
GI50 of these molecules in MCF-7 breast cancer cells was 23μM, 42 μM and 85 μM, 
for the hydroquinone, quinone and trimethoxy variants, respectively, suggesting that 
LYS112 
TYR125 
TRP148 
PHE138 
ASN37 
LYS44 
ASP40 ASP79 
 - 21 -
the flexible linker connecting the resorcinol and quinone rings may lower the 
effectiveness of these compounds in cells.   
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Figure 13. Chimeras of radicicol and geldanamycin. 
 
 Following the preparation of radamide, radester was synthesized to identify 
the optimal tether to connect the resorcinolic ester with the quinone.57 A seven-step 
synthesis afforded the quinone, and the antiproliferative activity of both the 
hydroquinone and quinone was evaluated against MCF-7 cells. Once again, the 
hydroquinone was more active than the quinone (GI50 = 7 and 14 μM, respectively) 
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and these activities correlated directly to the degradation of Hsp90-dependent client 
proteins Her2 and Raf-1.  
 With an optimized ester and amide chain length identified, the macrocyclic 
radanamycin chimera was prepared and evaluated in MCF-7 breast cancer cells. This 
compound exhibited a GI50 value of 1.2 μM, which correlated directly with the 
degradation of Hsp90 clients Her2 and Akt.58  
 The ability to simultaneously elucidate structure–activity relationships for 
both GDM and RDC with these chimeric inhibitors proved useful for the preparation 
of improved analogues of the corresponding natural products. Recently, researchers at 
Infinity Pharmaceuticals determined that the hydroquinone of 17-AAG is the active 
species in cancer cells and that this compound maintains higher affinity for Hsp90 
than the corresponding quinone. Consequently, the hydroquinone of 17-AAG became 
the first natural product-based Hsp90 inhibitor to enter Phase I clinical studies for the 
treatment of cancer.  
C-terminal inhibitors.  In 2000, Neckers and coworkers made another 
significant contribution to the Hsp90 field of research.  It had been previously noted 
that geldanamycin adopted a cup-shaped conformation when bound to the Hsp90 N-
terminal ATP-binding pocket.  Neckers and colleagues realized that novobiocin, a 
natural product used clinically in Europe as an antibiotic, exhibited a similar cup 
shape when bound to its cognate protein, DNA gyrase (Fig. 14).   
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Figure 14.  A) Geldanamycin (green) bound to Hsp90 and B) novobiocin (magenta)  
         bound to DNA gyrase. 
 
As members of the GHKL superfamily, which is composed of the proteins 
Gyrase, Hsp90, histidine Kinase, and MutL, these proteins share many common 
attributes with regard to the structure of their ATP-binding domains.  It was 
hypothesized that novobiocin might, therefore, act as an Hsp90 inhibitor, which was 
subsequently proven via assays in which novobiocin was shown to bind both purified 
Hsp90 and Hsp90 from cell lysates.  Furthermore, novobiocin was able to deplete 
Hsp90 client proteins p185erbB2 and Raf-1 in a concentration-dependent manner.59  
However, in subsequent studies with geldanamycin and radicicol, it appeared 
as though novobiocin did not compete with these inhibitors at the N-terminal ATP-
binding site.59 Following deletion/mutation analyses by Marcu et. al. using truncated 
fragments of Hsp90, it was concluded that novobiocin bound to a previously 
unrecognized binding site located within the C-terminal domain.60  Thus began 
studies of a new class of small molecule inhibitors of the Hsp90 C-terminus.  
A B 
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In addition to novobiocin, which was the first identified inhibitor of the Hsp90 
C-terminus, other aminocoumarin antibiotics such as clorobiocin and the dimeric 
compound, coumermycin A1, have also been shown to exhibit C-terminal inhibitory 
activity, demonstrating IC50 values of 350 μM and 70 μM, respectively, against MCF 
cells.  Additionally, derrubone, a flavonoid natural product that was recently 
discovered to inhibit Hsp90 (IC50 value 14μM), is believed to bind the C-terminus.61 
 
 (Fig. 15).61   
 
 
 
 
 
 
 
 
 
 
Figure 15.  Natural product C-terminal Hsp90 inhibitors. 
 
Novobiocin analogues have become promising lead compounds for a number 
of efforts toward the synthesis and development of highly potent and selective Hsp90 
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inhibitors.  Further studies aimed toward the understanding of how these compounds 
interact with the C-terminus may provide clinically useful compounds that can be 
used as alternatives to Hsp90 N-terminal inhibitors.   
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Results and Discussion 
Synthetic efforts toward new analogues of novobiocin.  Since the 
identification of novobiocin as a C-terminal Hsp90 inhibitor in 2000, studies have 
been underway in the Blagg Laboratory to produce more efficacious and selective 
analogues of this natural product.  The structure of this molecule can be considered as 
three separate moieties: the benzamide side chain, the central coumarin core, and the 
noviose sugar (Fig. 16).   
 
 
 
 
 
 
 
Figure 16.  Novobiocin, a C-terminal Hsp90 inhibitor. 
 
Early synthetic efforts by the Blagg laboratory indicated that the benzamide 
side chain was critical to growth inhibitory activity; derivatives lacking this 
functionality were shown to manifest neuroprotective activity.  It was hypothesized 
that the mode of action was consistent with Hsp90 modulatory effects.62  Later, 
derivitization of the benzamide side chain led to improved analogues exhibiting as 
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much as a 1000-fold increase in activity over the parent compound, novobiocin, 
against a range of cancer cell lines.63 
 Derivatives of the coumarin core were also designed in an attempt to create 
more potent inhibitors.  It was determined in early studies that the hydroxyl group at 
the 4-position of the coumarin was detrimental to Hsp90 activity, and actually 
allowed for selectivity against DNA gyrase instead.64  Upon analysis of initial SAR, it 
was also noted that a methyl group in the 8-position gave nearly a ten-fold 
improvement over the parent compound, which contains a hydrogen at the 8-position.  
Additionally, the natural product clorobiocin contains an 8-chlorocoumarin moiety 
which was twice as active as novobiocin against SKBr3 cells.   
Further derivatives of the 8-position were therefore synthesized to determine 
the depth and characteristics of the binding pocket into which this moiety projects, 
including various 8-alkyl, -aryl, and –halide groups.  Benzoyl protection of the 
glycine amine was followed by esterification using thionyl chloride and methanol.  
Upon treatment of the methyl ester with diformamide dimethyl acetal, it was possible 
to access the vinylogous carbamate, which was a common intermediate for the 
synthesis of the 8-R position coumarins via the corresponding 2-R position 
resorcinols (Scheme. 2).   
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Scheme 2.  General synthesis of 8-position coumarin derivatives. 
 
With synthetic efforts and further evaluation underway to pursue more 
effective coumarin analogues, the final focus to complete preliminary SAR studies of 
novobiocin was to pursue the noviose appendage.  Preliminary work reported by the 
Blagg Laboratory in 2005 showed that modifications to the 3’-carbame moiety of the 
sugar affected Hsp90 inhibitory activity, and it was hypothesized that further SAR 
would lead to significant improvements in efficacy.62  Previously accessed by our 
laboratory for the construction of other analogues, noviose can be isolated after 11 
steps in an overall yield of 8%.65 The synthesis, as shown in Scheme 3, involves harsh 
conditions, expensive reagents, and multiple purifications, effectively hindering 
synthetic progress.  Therefore, the design and synthesis of simple sugar mimics was 
proposed to yield novel novobiocin derivatives exhibiting improved potency, 
selectivity, and ease of accessibility over those containing the noviose sugar. 
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Scheme 3.  Synthesis of noviose. 
 
 In order to determine accurate structure–activity relationships for sugar 
mimics, it was necessary to couple them to a common scaffold.  We therefore chose 
the 8-methyl coumarin core, coupled to the biaryl acid that had produced consistent 
and potent inhibitory activity against several cancer cell lines.  The synthesis of this 
scaffold (Scheme 4), involved acetate protection of the 7-position phenol of the 
coumarin moiety, followed by removal of the Cbz protecting group using standard 
hydrogenolysis conditions to afford free amine 3.  Simultaneously, Suzuki conditions 
were employed utilizing methyl 3-iodo-4-methoxybenzoate and 3-methoxyphenyl-
boronic acid to yield the biaryl methyl ester shown. Hydrolysis of the ester occurred 
in near-quantitative yield using lithium hydroxide in a mixture of tetrahydrofuran, 
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water, and methanol, providing carboxylic acid 5, for subsequent coupling to the 
previously described amine, which was carried out under standard peptide coupling 
conditions enlisting EDCI.  The entire scaffold was then subjected to lithium 
hydroxide or triethylamine in order to solvolyze the cyclic carbonate and afford 
phenol 6 for coupling to sugar mimics.   
 
O
NHCbz pyr., Ac2O
95%HO O O
NHCbz
AcO O O
NH2
AcO O
H2, Pd/C
quant.
1
O
O
O
HO
O
O
O
O
O
O
O
I
LiOH
95%
O
B
HO OH
KOH
Pd(dppf)Cl2
65-78%
5
O
O
O
HO
OAcO
NH2
O
3
O
O
O
H
N
O OHO
1) EDCI, pyr.
45%
2) LiOH
90%
2 3
4 5
6
 
Scheme 4.  Synthesis of scaffold. 
 
Initial sugar analogues, completed by the O’Doherty laboratory at West 
Virginia University, were evaluated for anti-proliferative activity, with all three 
derivatives exhibiting increased potency over parent compound KU-111 (Fig. 17).  
The data from these KU-111 derivatives indicated that the sugar moiety did, in fact, 
play a critical role in the binding interactions of novobiocin to Hsp90.  Therefore, in 
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an effort to further elucidate structure-activity relationships, to streamline the overall 
syntheses of the novobiocin family C-terminal inhibitors, and to produce more 
efficacious small molecules, we set out to pursue a library of noviose mimics. 
 
 
Figure 17.  Anti-proliferative activity (in μM) of analogues with KU-111 scaffold. 
  
We designed a library of racemic cyclohexanol derivatives, to be accessed via 
procedures between one and six steps in length, a significant improvement over the 
synthesis of noviose.  The specific binding interactions of the parent compound are 
unknown, since a co-crystal structure has yet to be determined for any C-terminal 
inhibitors.  These mimics, therefore, were designed with either nitrogen or oxygen 
heteroatoms at various positions within the ring structure to probe the hydrogen-
bonding interactions with the binding pocket and to provide derivatives that exhibit 
improved solubility.  Additionally, since all three derivatives from the original series 
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(Fig. 17) exhibited increased inhibitory effects over KU-111 and contained a single 
methyl group instead of the gem-dimethyl moiety present on the parent compound, 
derivatives with both these variations, as well as a di-desmethyl derivative were 
designed.  Finally, the initial series aimed to determine whether the diol was a 
necessary component for Hsp90 inhibition, therefore, derivatives with and without 
this functionality were proposed as well (Fig. 18).   
 
 
 
 
 
 
 
 
 
Figure 18.  Library of sugar mimics. 
  
Many of these simplified versions of the sugar moiety were accessible using 
common procedures (Scheme 5), such as one-pot reductions with lithium aluminum 
hydride to produce compounds 7 and 8, or via Luche conditions to yield 9.  An 
oxidation procedure afforded alcohol 10 from dihydropyran, and compounds 11 and 
12 were purchased commercially. Compounds containing a double bond were 
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designed to be coupled to the scaffold and subsequently dihydroxylated to give the 
corresponding diols for comparison.  The procedures utilized gave moderate to 
excellent yields, and all were significantly more succinct than the synthetic route to 
noviose.   
 
 
 
 
 
 
 
 
Scheme 5.  Synthesis of sugar mimics. 
 
While formylation and acetylation of nitrogen-containing derivatives 13 and 
14 proceeded with great chemoselectivity in one step without the need for protection 
or deprotection (Scheme 6), the two compounds that contained a double bond 
presented a greater synthetic challenge.  Butadiene monoxide and allylamine were 
coupled using a catalytic amount of water to afford bis-alkene intermediate 15.  The 
route bifurcated at this point, and we used similar conditions as before to protect the 
secondary amine as either the N-methyl or N-acetyl moiety to make respective 
derivatives 16 and 17.  The alcohols were initially protected using tert-butyl dimethyl 
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silyl groups prior to ring-closing metathesis (RCM), but this was later found 
unnecessary, since RCM can occur readily in the present of an allylated alcohol, 
resulting in improved yields and fewer steps to achieve 18 and 19.66  RCM was also 
successful in much higher yields using Grubbs’ second generation catalyst than with 
the first generation variant, which we hypothesized was the result of greater 
functional group tolerance.  Additionally, only destabilized dichloromethane provided 
the solubility and the inert environment for these RCM reactions to occur.   
 
 
 
 
 
 
 
 
 
 
Scheme 6.  Synthesis of nitrogen-containing sugar mimics. 
 
Difficulties arose upon attempting to form the etheral linkage between the 
coumarin scaffold and various cyclohexanol derivatives.  When coupling to noviose 
or other sugars, a Lewis acid-catalyzed procedure was utilized, however, when 
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coupling to derivatives that lacked the anomeric oxygen, this route did not provide 
any desired products.  Additional efforts included tosylation and triflation of the 
alcohols, in hopes that the phenol could facilitate an SN2–type displacement under 
basic conditions.  However, these were ineffective and produced only trace amounts 
of product, if any, perhaps due to the inefficient nucleophilicity of the phenolic 
oxygen.   
 We changed our strategy at this point to the esterification protocol developed 
by Mitsunobu et. al.67 These procedures normally involve the use of triphenyl-
phosphine (PPh3) and a reactive azide species such as diethylazodi-carboxylate 
(DEAD).  The triphenyl phosphine nucleophilically attacks the azo species, yielding a 
betaine intermediate species, which in turn deprotonates the phenol.  The resulting ion 
deprotonates the alcohol, leaving the resultant alkoxide to form the critical 
oxophosphonium species and activating it as a leaving group, which is subsequently 
attacked by the phenolic anion to form the desired ether linkage (Scheme 7).68 
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Scheme 7.  Mechanism of the Mitsunobu esterification reaction  
         and common reagents. 
 
 After initial attempts to couple the alcohols with the coumarin phenol moiety, 
it was proposed that the very low acidity of the phenol might prevent successful 
conversion.  We therefore switched to the more reactive isopropyl derivative of 
DEAD, known as DIAD (diisopropylazodicarboxylate), and when these conditions 
also failed to yield the desired ether, an even more reactive species, 1,1’-
(azodicarbonyl)dipiperidine (ADDP) was utilized (Scheme 7).  Though Mitsunobu 
esterification can often proceed in a one-pot fashion, it was necessary to first form the 
betaine intermediate, followed by addition of the alcohol and then the phenol.  A 
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variety of temperatures and solvents were also tested in order to provide optimal 
conditions (Table 2).   
 
 
 
Molar Equivalents Solvent ROH ArOH PPh3/ADDP 
Temperature Yield 
CH2Cl2 
1.0 
1.0 
1.0 
1.0 
2.0 
2.0 
1.5 
2.0 
1.5 
0 - 25oC 
0 – 25oC 
0 – 25oC 
-- 
trace 
<5% 
THF 
1.0 
2.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
2.0 
2.0 
2.0 
2.0 
1.5 
1.5 
1.5 
1.3 
1.3 
1.3 
0 - 25oC 
0 – 25oC 
0 – 25oC 
0 – 25oC 
25oC 
50oC 
trace 
trace 
8% 
35% 
42% 
22% 
benzene 1.0 2.0 1.3 25oC -- 
toluene 
1.0 
1.0 
1.0 
2.0 
2.0 
5.0 
1.3 
1.3 
2.0 
0 – 25oC 
25oC 
25oC 
trace 
13% 
-- 
 
Table 1.  Mitsunobu esterification conditions and results. 
 
 Although we did obtain products via these conditions, it was noted that the 
reactions proceeded much more efficiently when building each molecule separately, 
coupling each sugar mimic to the coumarin core before appending the benzamide side 
chain.  Although this prevented us from taking advantage of common intermediates, it 
did result in improved overall yields for each of the three compounds, 22a-c, as 
shown in Scheme 8.  However, this later-developed strategy is not able to be utilized 
for those compounds which undergo further dihydroxylation or subsequent 
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functionalization, due to the reductive side reactions that occur during the palladium-
catalyzed hydrogenolysis used to cleave the Cbz group. 
 
 
Scheme 8.  Secondary route to access novobiocin analogues. 
  
Further work to complete these final compounds, and others, for a full library 
of novobiocin derivatives containing sugar mimics is currently underway.  Other 
ongoing efforts include the synthesis of five- and seven-membered sugar mimics, as 
well as cyclic alcohols with varying substituents about the ring, following previous 
work reported by the Blagg Laboratory.  Future anti-proliferative assays and other 
biological studies will complete analyses of these analogues, which are hypothesized 
to show demonstrate improvements in selectivity and potency, as well as to provide 
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critical structure-activity relationships regarding the interaction of novobiocin 
derivatives with the Hsp90 C-terminus.   
Computational studies.  Structure-based drug design is frequently employed 
to design and evaluate potential inhibitors of the Hsp90 N-terminus in order to 
improve the efficiency of synthetic efforts.  This is made possible by studying co-
crystal structures of geldanamycin and radicicol within the N-terminal ATP-binding 
domain, removing the bound ligand and then using molecular docking programs to 
evaluate a ligand of choice.  Comparisons of resultant binding energies, coupled with 
observations about relevant binding interactions within the pocket in question are 
used to determine which molecules demonstrate the highest affinity and, therefore, 
are worth synthesizing in the laboratory.  In the absence of a co-crystal structure 
representing the Hsp90 C-terminus bound to an inhibitor, docking studies and 
comparisons present a significant challenge, as the correct conformation of the 
protein structure is based on similarity to other proteins or crystal structures alone.   
Full-length crystal structures of Hsp90 reveal that the protein maintains an 
active dimer, exhibiting C2 symmetry.69 Monomers of Hsp90 are known to be 
inactive;69 it follows that inhibition of the dimerization domain would prevent the 
protein from assuming its active conformation and would lead to efficacious and 
selective Hsp90 inhibitors.  The dimerization domain resides within the C-terminus of 
the protein, and contains four overlapping alpha-helices of various compositions.  
This is also proposed to be the site to which novobiocin and other C-terminal 
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inhibitors bind and inhibit the protein, although studies to date have been 
inconclusive and do not fit the structures provided by solution or crystal structures.   
Several groups have proposed binding sites within the C-terminal domain, and 
suggest this region of the protein exists in both open and closed conformations, with 
inhibitors preventing dimerization.60,70 However, available crystal structures do not 
exhibit an intact dimerization region with open nucleotide–binding motifs (Fig. 19).  
Furthermore, none of the theoretical binding sites proposed to date match the 
biochemical results obtained for Hsp90. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 19. C-terminal crystal structure in open conformation with proposed  
   binding sites 535-EFEGKT-540 and 559-KKQEEKKT-566. 
 
Dimerization Region 
535-EFEGKT-540 
559-KKQEEKKT-566 
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To alleviate this problem and to design a working model for the Hsp90 C-
terminus to be used for computational predictions prior to synthetic efforts, the Blagg 
Laboratory produced four photolabile novobiocin analogues (Fig. 20) to be used in 
photoaffinity studies in collaboration with the Matts Laboratory at Oklahoma State 
University.71  After binding of these derivatives to Hsp90, they were irradiated with 
ultraviolet light to cleave the azide moiety, producing a reactive nitrene species, 
which underwent insertion into the C-terminal backbone.  Following trypsin digests 
to cleave the protein at serine and threonine residues, the fragments were analyzed via 
mass spectrometry to determine the location at which the compounds inserted.  These 
studies identified two previously unrecognized binding sites within the C-terminus, 
535-EFEGKT-540 and 559-KKQEEKKT-566 (Fig. 19), and provided new insights 
into the putative binding pocket.  
 
 
 
 
 
 
 
 
Figure 20.  Photolabile novobiocin analogues. 
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Initial molecular docking studies with the only published C-terminal Hsp90 
crystal structure, 2CGE, were performed in order to test the validity of this crystal 
structure for future structure-based design of analogues.  A library of 100 ligands was 
generated using the Sybyl “Build” component, including 45were performed in order 
to test the validity of this crystal structure for future structure-based design of 
analogues.  A library of 100 ligands was generated using the “build” component of 
the Sybyl software by Tripos, then analyzed via docking procedures within this 
framework. This series was designed with a broad range of structural variations and 
included natural products novobiocin, clorobiocin, derrubone, and coumermycin A1, 
along with derivatives of these compounds for which we had already obtained IC50 
values in MCF-7 and SKBr3 cell lines.  
Docking analyses were performed using the Autodock functionality, which 
provides approximations of the intermolecular energy interactions between the 
protein and ligand in kcals/mol, and can be used to determine potential binding sites 
and favorable conformations for the ligands of choice.  Flexidock, another docking 
program used to supplement the information obtained, allows additional flexibility 
within the protein, which can be specified to the proposed active site.  The algorithm-
based Flexidock program also conducts calculations that account for electrostatic, 
torsional, and constraint energy terms to provide computational hypotheses for how 
each ligand may bind to the protein.    
Results suggested the ligands bound randomly at sites unrecognized as critical 
regions within the 2CGE structure.  Hypothesizing that the protein would exhibit 
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different conformations when binding in vivo, we set out to build new models that 
would exhibit a preferred conformation and provide pockets for ligand interaction. 
Using SwissModel and PyMol programs, which allow manipulation of the secondary 
and tertiary Hsp90 C-terminal and full-length protein structures, a series of four 
models was built M1P-M4P, each presenting different amino acids within the 
binding site in an attempt to optimize protein-ligand interactions (Fig. 21).   
Preliminary structure-activity relationships, based on the MCF-7 and SKBr3 
cells antiproliferation values obtained experimentally, were used to predict which 
amino acid residues within the C-terminal domain might be critical for binding.  This 
included manipulation of aromatic residues, such as Phe536, into the open pocket in 
an attempt to facilitate stacking interactions with the coumarin ring of our novobiocin 
analogues.  M1P and M4P were both based on full-length Hsp90 crystal structure 
2CG9, while M2P and M3P were modeled after 2CGE.  These four models were 
converted into Sybyl Unix language format and hydrogen atoms were inserted to 
allow hydrogen-bonding capabilities.    
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Figure 21.  Ribbon diagrams of original model series M1P-M4P. 
 
These four models were screened against the ligand library and evaluated for 
binding affinities.  Preliminary investigation suggested that none of the analogues 
bound to sites identified via the photoaffinity binding studies.  However, the best of 
these models, M1P, showed the ligands docked in an area proximal to an alternative 
M1P M2P (C-terminus) 
M3P (C-terminus) M4P 
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location (Fig. 22).  It was hypothesized that the flexibility of the protein might allow 
rotation upon binding to form interactions with the biochemically elucidated site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Novobiocin derivative KU-111 bound to model M1P. 
 
Based on analyses of these docking studies, which include overlays of each 
ligand bound to its respective binding site, four new models, 1-4CT, were designed 
using SwissModeler and PyMol.  This set of structures was designed with the alpha 
helices of the dimerization domain in closer proximity to one another, based on our 
hypothesis that the ligands bind as the Hsp90 monomers approach their preferred 
conformation for dimerization.  We also proposed that the monomers may rotate to a 
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greater degree than originally shown in the M1P model series, creating a pocket 
containing the KKQEEKKT domain, therefore the CT model series also accounted 
for this possibility while maintaining the C2 symmetry of the C-terminus (Fig. 23).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.  Second model series, 1-4CT. 
1CT 2CT 
3CT 4CT 
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These models were converted into Sybyl format and evaluated using the 
Autodock and Flexidock molecular docking protocols.  Model 3CT was identified as 
the best in the series, based on the consistency of the binding results and the favorable 
enthalpic values produced upon docking.  The overlapping alpha helices of the 
dimerization region exhibited by the CT series also allowed some of the dimeric 
coumermycin A1 analogues to dock simultaneously at similar regions on each of the 
two Hsp90 monomers.  Although this data does not correspond to our experimental 
biochemical results, it provides useful information for further model design, 
indicating which residue conformations might allow or prevent accurate binding of 
the ligands within the C-terminal domain.  
The CT studies showed consistent results with respect to docking location and 
orientation, as well as binding energies.  The 100-ligand docking screen exhibited 
theoretical binding capabilities consistent with experimentally obtained in vitro data.  
For example, those compounds with the biaryl (KU-111B) or indole (KU-122) side 
chains were shown to have greater Hsp90-binding interactions (Fig. 24) compared to 
the parent compound, which correlates with the improved IC50 values for these 
analogues.  However, subsequent review demonstrated that the amino acids shown to 
be critical for binding in these computational studies, 670-ALLSSGFSL-678, did not 
correlate with those identified via photoaffinity studies.   
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Figure 24.  Analogues KU-111B and KU-122, docked to model 3CT. 
 
In early 2008, Bron et. al. published the first solution structures for apo-
Hsp90, illustrating the vast magnitude of conformational changes of the Hsp90 
protein and providing new insights toward the development of an accurate binding 
model of the C-terminus.72   Based on these solution structures, we revised our earlier 
models, opening the bridge to the middle domain of Hsp90 and further rotating the C-
670ALA 
669THR 
671LEU 
672LEU 
673SER 
674SER 
6675GLY 
676PHE 677SER 
678LEU 
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terminal monomers to produce three new models, EM1-3 (Fig. 25).  These models 
showed more similarity with the published figures while also maintaining exposure to 
our identified binding sequences, EFEGKT and KKQEEKKT.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Model series EM1-3. 
EM1 EM2 (C-terminus) 
EM3 
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 As before, we screened both full-length models (EM1 and EM3) and one that 
included only the C-terminal residues (EM2) in an attempt to ensure that theoretical 
binding did not occur at other locations within the Hsp90 protein structure.  Analyses 
of the docking results for the EM series showed ligands bound in an entirely different 
region, much closer to the middle domain than had been proposed by our previous 
computational models (Fig. 26).  Additionally, although these results exhibited some 
of the predicted ligand-amino acid interactions, the overall data still did not match the 
regions that had been identified via photoaffinity experiments.  It was hypothesized 
that the very open structure of these models allowed the ligands to bind regions that 
would not be accessible in vivo, thus accounting for the inaccuracy of these results.  
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  KU-122 bound to model EM1. 
VAL296 
THR274 
CYS305 
PHE276 
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Overall, these results led us to conclude that the rigidity of both protein and 
ligand that is maintained in the Sybyl docking programs may prevent exposure of the 
ligand to the proper binding site.  Addtionally, these docking algorithms do not bias 
the ligands to bind in a preferred site, and therefore other favorable interactions with 
the C-terminal backbone may interfere.  Recent x-ray crystallography analyses of the 
E. coli Hsp90 homolog, htpG, by the Agard laboratory also provided new insight into 
the distinct conformations assumed by the protein in its open form, with no bound 
ligand, and in its closed form, after ATP or another ligand binds in the N-terminal 
domain.73  This supplements earlier studies with geldanamycin and radicicol that 
show the C-terminal binding domain only becomes accessible after ATP or an 
inhibitor is bound to the N-terminus, suggesting that the dimerization domain of the 
protein undergoes radical conformational changes during this process.    
Further studies involving the building of new models are currently underway, 
utilizing docking programs such as Surflex by Tripos, which allow for analysis 
specific to a proposed binding pocket.  The InsightII Affinity package from Accelrys, 
Inc., has also shown promise, as this docking module includes dynamics simulations 
to overcome structural rigidity and to allow for protein movement close to the binding 
area.  Comparative Molecular Field Analysis (CoMFA) studies are also in progress in 
hopes of obtaining useful in silico information for the prediction of efficacious new 
analogues of novobiocin and other C-terminal Hsp90 inhibitors.   
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Summary.  This investigation has shown the continued synthetic efforts 
toward novel analogues of C-terminal Hsp90 inhibitor novobiocin.  Structure-activity 
relationship studies of the coumarin and benzamide moieties of this molecule have 
yielded compounds with increased potency and may become clinical alternatives to 
N-terminal Hsp90 inhibitors. This study includes the design and synthesis of key 
derivatives of the noviose sugar, which will provide critical structure-activity 
relationship information upon biological evaluation. Additionally, this investigation 
has shown the design and analysis of numerous models of the Hsp90 C-terminus in an 
attempt to elucidate a model that can be used for future structure-based drug design.  
Continued synthetic and computational efforts in this area will lead to a better 
understanding of the interactions between Hsp90 and C-terminal inhibitors.   
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Experimental Data 
 General Methods. 1H and 13C NMR spectra were obtained on a Bruker DRX-
400 instrument (400 MHz and 100.6 MHz, respectively).  The samples were 
dissolved in CDCl3.  Chemical shifts are expressed in parts per million (δ) relative to 
the residual CHCl3 serving as an internal standard.  Abbreviations are as follows: s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.  Low resolution mass 
spectra (ES+, electrospray ionization, or FAB+, fast atom bombardment) were 
obtained using a Ribermag R10-10 quadrupole instrument.  High resolution mass 
spectra (HRMS) were obtained using a VG Analytical ZAG double focusing 
spectrometer. All chromatographic separations were performed using Sorbent 
Technologies silica gel (230-400 mesh) or Analtech preparative layer TLC plates 
(250 or 1000 microns) with solvent mixtures as indicated. Benzene, dichloromethane, 
ether, tetrahydrofuran, and toluene (when used as reaction solvents) were purchased 
from Fisher Scientific and purified in a solvent purification system.  All other 
solvents were purchased from Acros, Fisher Scientific, or Sigma-Aldrich and were 
used without further purification.  All reactions that were not run in a reaction 
medium with water as a co-solvent were conducted in oven- or flame-dried reaction 
flasks that were cooled under argon.  All reactions, unless otherwise specified, were 
performed in inert atmosphere under argon.   
 Materials.  All reagents were purchased from Acros or Sigma-Aldrich 
chemical companies and used as received.   
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Experimental Section 
The following compounds have been published by our laboratory: benzyl 7-
hydroxy-8-methyl-2-oxo-2H-chromen-3-ylcarbamate (1),63 3-(benzyloxycarbonyl-
amino)-8-methyl-2-oxo-2H-chromen-7-yl acetate (2),63 3-amino-8-methyl-2-oxo-2H-
chromen-7-yl acetate (3),63 methyl 3’,6-dimethoxybiphenyl-3-carboxylate (4),63 3’,6-
dimethoxybiphenyl-3-carboxylic acid (5),63 and N-(7-hydroxy-8-methyl-2-oxo-2H-
chromen-3-yl)-3’,6-dimethoxybiphenyl-3-carboxamide (6).63  
The following compounds are known in the literature: cyclohex-2-enol (9),74 
tetrahydro-2H-pyran-3-ol (10),75 tetrahydro-2H-pyran-2-ol (11),76 tetrahydro-2H-
pyran-4-ol (12),76 and 1-methylpiperidin-3-ol (13).77  
 
 
    (7) 
 5,5-dimethylcyclohex-2-enol (7). Procedure adapted from literature.78 5,5-
dimethylcyclohexan-2-dione (1.0 g, 7.2 mmol) was added slowly to a solution of 
LiAlH4 (0.35 g, 9.2 mmol) in anhydrous Et2O (40 mL) at reflux.  The mixture was 
stirred at reflux for six hours, cooled to 0oC, then quenched by dropwise addition of 
H2O.  The resulting suspension was extracted with Et2O (3 x 50 mL). The combined 
organic layers were washed with water, brine, and dried (Na2SO4).  The resulting oil 
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was purified via vacuum distillation to provide 7 as a colorless oil (0.49 g, 54%); (b.p. 
68-70oC).    
 
     8 
 5-methylcyclohex-2-enol (8).  Procedure adapted from literature.78 5-methyl 
cyclohexan-2-dione (1.0 g, 8.0 mmol) was added slowly to a solution of LiAlH4 (0.39 
g, 10 mmol) in anhydrous Et2O (40 mL) at reflux.  The mixture was stirred at reflux 
for six hours, cooled to 0oC, and then quenched by dropwise addition of H2O.  The 
resulting suspension was extracted with Et2O (3 x 50 mL). The combined organic 
layers were washed with water, brine, and dried (Na2SO4).  The resulting oil was 
purified via vacuum distillation to provide 8 as a colorless oil (0.56 g, 62%); (b.p. 65-
70oC). 
 
 
14 
1-(3-hydroxypiperidin-1-yl)ethanone (14).  3-hydroxypiperidine (5.0 g, 49.5 
mmol) was dissolved in a solution of pyridine (30 mL) and acetic anhydride (10 mL).  
The mixture was stirred overnight at rt.  Solvent was removed in vacuo.  The 
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resulting yellow solid was redissolved in EtOAc (10 mL) and diluted to 50 mL with 
H2O, then extracted with EtOAc (3 x 50 mL).  The combined organic layers were 
washed with brine, dried (Na2SO4), filtered, and concentrated to produce a yellow 
residue that was purified via column chromatography (5:1-2:1 hexanes:EtOAc) to 
provide 14 as a yellow amorphous solid (6.3 g, 90%); Rf = 0.48 (2:1 hexanes:EtOAc). 
1H NMR (400 MHz, CDCl3) δ: 1.46 (m, 1H), 1.52 (m, 2H), 1.77 (m, 1H), 2.10 (s, 
3H), 3.27 (m, 1H), 3.30 (br, 3H), 3.56 (m, 1H), 3.66 (br, 1H).  13C NMR (100.6 MHz, 
CDCl3) δ: 21.7, 23.5, 32.5, 49.4, 52.0, 70.0, 172.8.  MS (FAB) m/z 143 (M+1); 
HRMS (ES+) calcd for C7H13NO2Na (M+Na): 166.0946, found 166.0950. IR (neat): 
3420, 2950, 1670 cm-1. 
 
            
 15             16             17 
 1-(allylamino)but-3-en-2-ol (15), 1-(allyl(methyl)amino)but-3-en-2-ol (16), 
and N-allyl-N-(2-hydroxybut-3-enyl)acetamide (17) .  To a solution of allylamine 
(20 mL, 47.1 mmol) and H2O (1.2 mL, 66.0 mmol) at 0oC was added butadiene 
monoxide (7.1 mL, 38.0 mmol) dropwise.  The resulting mixture was stirred at reflux 
for 16 hours before cooling to rt and in vacuo to produce 15 as an off-white solid. The 
product was used as is without further purification.   
HCOH, 
HCO2H 
 
or 
Pyr, Ac2O 
or 
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(16): 1.0 g of 15 was dissolved in H2O (5.0 mL).  This solution was added 
dropwise to a stirring solution of 88% formic acid (4.4 mL, 96 mmol) and 37% 
formaldehyde (2.2 mL, 80 mmol) at 0oC under argon.  The solution was warmed to rt  
and stirred for 1 hour before stirring at reflux overnight.  After cooling to 0oC, a 50% 
aqueous NaOH solution was added to pH 9-10.  Mixture was extracted with Et2O (3 x 
45 mL) and the combined organic layers were dried (Na2SO4), filtered, and 
concentrated in vacuo to produce a viscous yellow oil that was purified via column 
chromatography (5:1-1:1 hexanes:EtOAc) to provide 16 as a yellow oil (0.79 g,  
72%); Rf = 0.84 (2:1 hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 2.27 (s, 3H), 
2.44 (m, 1H), 2.56 (m,1H), 2.96 (br, 1H), 3.11 (m, 2H), 4.25 (m, 1H), 5.16 (d, 1H), 
5.22 (m, 2H), 5.39 (d, 1H), 5.83 (m, 2H). 13C NMR (100.6 MHz, CDCl3) δ: 43.0, 
63.0, 65.7, 70.1, 115.8, 117.0, 134.3, 136.1.  MS (ES+) m/z 142.1. (M+1). IR (neat): 
3390, 3010, 1370, 920, 890 cm-1.  
(17): 1.0 g of 15 was dissolved in a solution of pyridine (18 mL) and acetic 
anhydride (6 mL).  The mixture stirred overnight at rt.  The solvent was removed in 
vacuo, and the resulting yellow solid was redissolved in EtOAc (10 mL), diluted to 50 
mL with H2O, and extracted with EtOAc (3 x 50 mL).  Combined organic layers were 
washed with brine, dried (Na2SO4), filtered, and concentrated to produce a yellow 
residue that was purified via column chromatography (5:1-2:1 hexanes:EtOAc) to 
provide 17 as a light yellow amorphous solid (1.12 g, 84%); Rf = 0.78 (2:1 
hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 2.30 (s, 3H), 3.12 (m, 1H), 3.41 (m, 
1H), 3.78 (m, 1H), 4.44 (m, 1H), 5.20 (br. m, 3H), 5.39 (d, 1H), 5.82 (br. m, 2H). 13C 
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NMR (100.6 MHz, CDCl3) δ: 22.4, 44.4, 54.2, 78.3, 115.0, 116.3, 130.1, 136.0, 
171.8.  MS (ES+) m/z 170.1 (M+1). IR (neat):  3350, 3100, 1640, 880, 860 cm-1.  
 
 
18 
1-methyl-1,2,3,6-tetrahydropyridin-3-ol (18).  To a solution of 16 (0.5 g, 
3.5 mmol) dissolved in destabilized CH2Cl2 (10 mL) was added Grubbs’ Second 
Generation Catalyst (0.17 g, 5 mol %) at rt.  The reaction stirred at rt for 12 hours.  
The solution was then eluted through a plug of silica gel using a 40:1 solution of 
CH2Cl2 and acetone.  The dark brown residue was purified via column 
chromatography (40:1 CH2Cl2:acetone) to afford 18 as an off-white solid (0.13 g, 34 
%); Rf = 0.79 (40:1 CH2Cl2:acetone). 1H NMR (400 MHz, CDCl3) δ: 2.25 (s, 3H), 
2.37 (m, 1H), 2.73 (m, 2H), 2.78 (m, 2H), 3.77 (m, 1H), 5.69 (m, 2H). 13C NMR 
(100.6 MHz, CDCl3) δ: 46.1, 56.0, 66.6, 71.0, 124.2, 128.1.  MS (ES+) m/z 114.1 
(M+1); HRMS (ES+) calcd for C6H11NONa (M+Na): 136.0841, found 136.0843.  IR 
(neat):  3420, 3080, 1240, 780 cm-1.  
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19 
1-(5-hydroxy-5,6-dihydropyridin-1(2H)-yl)ethanone (19).  To a solution of 
17 (0.5 g, 3.0 mmol) dissolved in destabilized CH2Cl2 (10 mL) was added Grubbs’ 
Second Generation Catalyst (0.12 g, 5 mol %) at rt.  The reaction stirred at rt for 12 
hours.  The solution was then eluted through a plug of silica gel using a 40:1 solution 
of CH2Cl2 and acetone.  The dark brown residue was purified via column 
chromatography (40:1 CH2Cl2:acetone) to afford 19 as a light yellow amorphous 
solid (0.12 g, 29%); Rf = 0.70 (40:1 CH2Cl2:acetone). 1H NMR (400 MHz, CDCl3) δ: 
2.33 (s, 3H), 3.49 (m, 1H), 3.76 (m, 1H), 3.92 (br. m, 3H), 5.70 (m, 1H), 5.75 (m, 
1H). 13C NMR (100.6 MHz, CDCl3) δ: 22.5, 44.0, 59.6, 70.8, 124.8, 127.9, 170.0. 
MS (ES+) m/z 141.1 (M+1); HRMS (ES+) calcd for C6H11NONa (M+Na): 164.0790, 
found 164.0791.   IR (neat): 3410, 3100, 1630, 1570, 820 cm-1. 
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20a 
Benzyl 8-methyl-2-oxo-7-(tetrahydro-2H-pyran-2-yloxy)-2H-chromen-3-
ylcarbamate (20a).  Triphenylphosphine (0.20 g, 0.76 mmol) was dissolved in 
anhydrous THF (5 mL) at rt.  A solution of ADDP (0.19 g, 0.76 mmol) in THF (1 
mL) was added dropwise to the PPh3 solution.  The mixture stirred for ten minutes 
before adding alcohol 11 (0.056 g, 0.55 mmol) dropwise. The resulting mixture 
stirred an additional ten minutes, then phenol 1 (0.4 g, 1.2 mmol) was dissolved in 4 
mL THF and cannulated into the solution.  The reaction stirred overnight at rt.  The 
resulting mixture was concentrated via a stream of argon and the residue purified via 
column chromatography (10:1-2:1 hexanes:EtOAc) to afford 20a as a yellow solid 
(0.095 g, 41%); Rf = 0.43 (2:1 hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 1.58 
(m, 2H), 1.68 (m, 2H), 1.89 (m, 1H), 2.07 (m,1H), 2.23 (s, 3H), 3.46 (m,1H), 3.53 
(m,1H), 5.25 (s, 2H), 5.71 (m, 1H), 7.16 (d, 1H), 7.35-7.49 (br. m, 7H), 8.27 (s, 1H). 
13C NMR (100.6 MHz, CDCl3) δ: 9.9, 19.8, 25.7, 31.8, 64.0, 64.8, 104.1, 110.2, 
112.9, 118.9, 120.8, 126.4, 127.0, 128.0, 129.2, 135.5, 150.1, 150.8, 152.9, 156.7, 
160.0.  MS (ES+) m/z 410.2 (M+1); HRMS (ES+) calcd for C23H24NO6 (M+1): 
410.1525, found 410.1528.  IR (neat):  2920, 1730, 1640, 1400, 1380, 1110, 840, 680 
cm-1. 
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20b 
Benzyl 8-methyl-2-oxo-7-(tetrahdro-2H-pyran-3-yloxy)-2H-chrome-3-yl-
carbamate (20b).  Followed general procedure to make 20a, using alcohol 10 (0.056 
g, 0.55 mmol). The resulting mixture was concentrated via a stream of argon and the 
residue purified via column chromatography (10:1-2:1 hexanes:EtOAc) to afford 20b 
as a light yellow solid (0.054 g, 24%); Rf = 0.40 (2:1 hexanes:EtOAc). 1H NMR (400 
MHz, CDCl3) δ: 1.61 (m, 2H), 1.72 (m, 2H), 2.07 (m, 1H), 2.37 (s, 3H), 3.83 (m, 
1H), 3.89 (m, 2H), 5.24 (2H), 7.13 (d, 1H), 7.26 (s, 1H), 7.38-7.43 (br. m, 7 H), 8.28 
(s, 1H). 13C NMR (100.6 MHz, CDCl3) δ: 10.1, 25.6, 30.2, 66.7, 69.6, 76.0, 79.1, 
111.2, 112.9, 118.9, 121.2, 126.4, 127.4, 128.2, 136.5, 150.3, 154.1.  MS (ES+) m/z 
410.2 (M+1); HRMS (ES+) calcd for C23H24NO6 (M+1): 410.1525, found 410.1526  
IR spectral data not available for this compound. 
 
 
20c 
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Benzyl 8-methyl-2-oxo-7-(tetrahdro-2H-pyran-4-yloxy)-2H-chromen-3-yl-
carbamate (20c).  Followed general procedure to make 20a, using alcohol 12 (0.056 
g, 0.55 mmol). The resulting mixture was concentrated via a stream of argon and the 
residue purified via column chromatography (10:1-2:1 hexanes:EtOAc) to afford 20c 
as a light yellow solid (0.043 g, 19%); Rf = 0.40 (2:1 hexanes:EtOAc). 1H NMR (400 
MHz, CDCl3) δ: 1.79 (m, 2H), 2.11 (m, 2H), 2.23 (s, 3H), 3.64 (m, 2H), 3.75 (m, 
2H), 3.89 (m, 1H), 5.16 (s, 2H), 6.85 (d, 1H), 7.32-7.58 (br. m, 7H), 8.26 (s, 1H). 13C 
NMR (100.6 MHz, CDCl3) δ: 10.0, 35.2, 62.6, 62.8, 66.7, 76.0, 111.8, 114.0, 118.6, 
120.0, 126.7, 127.0, 127.4, 128.2, 128.6, 135.9, 151.1, 151.7, 154.6, 155.9, 160.1.  
MS (ES+) m/z 410.2 (M+1); HRMS (ES+) calcd for C23H24NO6 (M+1): 410.1525, 
found 410.1524.  IR (neat):  2860, 1710, 1650, 1630, 1450, 1210, 1050, 1020, 870, 
710 cm-1.  
 
 
21a 
3-amino-8-methyl-7-(tetrahydro-2H-pyran-2-yloxy)-2H-chromen-2-one 
(21a).  20a (0.02 g, 0.049 mmol) was dissolved in THF (7 mL) at rt.  10% Pd/C 
(0.005 g, 10 mol %) was added at once.  The flask was flushed with argon (2x) and 
H2 (2x) before allowing to stir at rt under H2 atmosphere overnight.  The flask was 
again flushed with argon, then the resulting mixture was eluted through a one-inch 
 - 63 -
plug of silica gel (1:1 hexanes:EtOAc).  The collected solvent was concentrated via a 
stream of air to afford 21a as an off-white solid (0.013 g, quant. yield); Rf = 0.24 (2:1 
hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 1.57 (m, 2H), 1.69 (m, 2H), 1.91 
(m, 1H), 2.07 (m, 1H), 2.38 (s, 3H), 3.62 (m, 2H), 4.07 (br, 2H), 5.49 (m, 1H), 6.72 
(s, 1H), 6.98 (d, 1H), 7.38 (d, 1H). 13C NMR (100.6 MHz, CDCl3) δ: 9.9, 21.2, 25.8, 
31.0, 63.0, 103.5, 111.1, 114.2, 114.6, 121.0, 126.4, 138.3, 151.0, 157.8, 161.1. MS 
(ES+) m/z 276.1 (M+1). IR (neat):  3290, 2880, 1670, 1380, 1340, 700, 670 cm-1. 
 
 
21b 
3-amino-8-methyl-7-(tetrahydro-2H-pyran-3-yloxy)-2H-chromen-2-one 
(21b).  Followed general procedure to make 21a, starting from 20b (0.02 g, 0.049 
mmol).  After stirring overnight, the resulting mixture was eluted through a one-inch 
plug of silica gel (1:1 hexanes:EtOAc).  The collected solvent was concentrated via a 
stream of air to afford 21b as an off-white solid (0.013 g, quant. yield); Rf = 0.22 (2:1 
hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 1.58 (m, 2H), 1.90 (m, 1H), 2.10 
(m, 1H), 2.30 (s, 3H), 3.58 (m, 2H), 3.91 (m, 2H), 4.14 (m, 1H), 4.56 (br. s, 2H), 7.01 
(s, 1H), 7.22 (d, 1H), 7.38 (d, 1H).  13C NMR (100.6 MHz, CDCl3) δ: 9.9, 23.9, 29.2, 
69.8, 74.5, 77.9, 111.2, 113.7, 114.1, 120.0, 126.6, 138.2, 151.1, 158.2, 161.4. MS 
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(ES+) m/z 276.2 (M+1). IR (neat):  3310, 2880, 1660, 1350, 1290, 1160, 910, 820, 
750 cm-1. 
 
 
21c 
3-amino-8-methyl-7-(tetrahydro-2H-pyran-4-yloxy)-2H-chromen-2-one 
(21c).  Followed general procedure to make 21a, starting from 20c (0.20 g, 0.49 
mmol).  After stirring overnight, the resulting mixture was eluted through a one-inch 
plug of silica gel (1:1 hexanes:EtOAc). The collected solvent was concentrated via a 
stream of air to afford 21c as an off-white solid (0.012 g, 90%); Rf = 0.24 (2:1 
hexanes:EtOAc). 1H NMR (400 MHz, CDCl3) δ: 1.80 (m, 2H), 2.07, (m, 2H), 2.23 (s, 
3H), 3.61 (br. m, 4H), 4.01 (m, 1H), 4.44 (s, 2H), 6.89 (s, 1H), 7.18 (d, 1H), 7.45 (d, 
1H).  13C NMR (100.6 MHz, CDCl3) δ: 10.0, 35.1, 63.7, 75.8, 111.2, 112.8, 113.2, 
120.0, 126.5, 137.9, 151.8, 157.6, 160.2. MS (ES+) m/z 276.1 (M+1). IR spectral data 
not available for this compound.     
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22a 
3’,6-dimethoxy-N-(8-methyl-2-oxo-7-(tetrahydro-2H-pyran-2-yloxy)-2H-
chromen-3-yl)biphenyl-3-carboxamide (22a).  Amine 21a (0.013 g, 0.049 mmol) 
was dissolved in CH2Cl2 (3 mL) at rt.  Next, biaryl acid 5 (0.025 g, 0.098 mmol) was 
added in one step.  To this stirring solution was added EDCI (0.024 g, 0.123 mmol), 
followed by pyridine (1.5 mL).  The resulting mixture stirred at rt for 18 hours under 
argon.  The solution was concentrated via a stream of air and purified via preparative 
chromatography (40:1 CH2Cl2: acetone) to afford 22a as a white solid (0.010 g, 38 
%); Rf = 0.77 (40:1 CH2Cl2: acetone). 1H NMR (400 MHz, CDCl3) δ: 1.64 (m, 2H), 
1.71 (m, 2H), 1.91 (m, 1H), 2.09 (m, 1H), 2.27 (s, 3H), 3.73  (m, 2H), 3.91 (s, 3H), 
3.95 (s, 3H), 5.66 (m, 1H), 7.03 (d, 1H), 7.29-7.57 (m, 8H), 8.12 (s, 1H), 8.63 (d, 1H).  
13C NMR (100.6 MHz, CDCl3) δ: 10.1, 21.0, 25.1, 31.0, 55.8, 56.1,  62.0, 104.9, 
110.9, 111.3, 113.5, 113.8, 117.6, 120.2, 122.9, 125.9, 126.1, 128.0, 128.6, 130.1, 
130.4, 136.7, 138.3, 153.9, 155.5, 160.0, 163.1, 168.9.  MS (ES+) m/z 516.2 (M+1); 
HRMS (ES+) calcd for C30H29NO7Na (M+Na): 538.1944, found 538.1946.  IR (neat):  
3030, 2860, 1720, 1630, 1390, 1300, 1090, 870, 770 cm-1. 
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22b 
3’,6-dimethoxy-N-(8-methyl-2-oxo-7-(tetrahydro-2H-pyran-3-yloxy)-2H-
chromen-3-yl)biphenyl-3-carboxamide (22b).  Followed general procedure to make 
22a, starting from 21b (0.013 g, 0.049 mmol). The resulting solution was 
concentrated via a stream of air and purified via preparative chromatography (40:1 
CH2Cl2: acetone) to afford 22b as an off-white solid (0.006 g, 22 %); Rf = 0.68 (40:1 
CH2Cl2: acetone). 1H NMR (400 MHz, CDCl3) δ: 1.58 (m, 2H), 1.90 (m, 1H), 2.10 
(m, 1H), 2.30 (s, 3H), 3.58 (m, 2H), 3.91 (m, 2H), 3.96 (s, 3H), 4.01 (s, 3H), 4.14 (m, 
1H), 6.99 (d, 1H), 7.29-7.41 (br. m, 8H), 8.12 (s, 1H), 8.55 (s, 1H).  13C NMR (100.6 
MHz, CDCl3) δ: 9.6, 24.9, 30.0, 54.5, 55.1, 69.8, 76.2, 79.7, 110.8, 111.1, 114.4, 
118.9, 119.6, 121.1, 124.0, 125.5, 126.2, 126.4, 129.9, 132.2, 136.8, 137.1, 152.7, 
153.8, 159.4, 160.3, 169.0. MS (ES+) m/z 516.2 (M+1).  IR (neat): 2990, 2840, 1710, 
1450, 920, 780 cm-1. 
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22c 
3’,6-dimethoxy-N-(8-methyl-2-oxo-7-(tetrahydro-2H-pyran-4-yloxy)-2H-
chromen-3-yl)biphenyl-3-carboxamide (22c).  Followed general procedure to make 
22a, starting from 21c (0.012 g, 0.043 mmol). The resulting solution was 
concentrated via a stream of air and purified via preparative chromatography (40:1 
CH2Cl2: acetone) to afford 22c as an off-white solid (0.006 g, 28%); Rf = 0.73 (40:1 
CH2Cl2: acetone). 1H NMR (400 MHz, CDCl3) δ: 1.81 (m, 2H), 2.09, (m, 2H), 2.21 
(s, 3H), 3.60 (br. m, 4H), 3.86 (s, 3H), 3.89 (s, 3H), 3.94 (m, 1H), 6.98 (d, 1H), 7.30-
7.49 (br. m, 8H), 8.18 (s, 1H), 8.45 (s, 1H). 13C NMR (100.6 MHz, CDCl3) δ: 9.9, 
26.2, 30.0, 56.2, 57.8, 71.0, 73.7, 78.9, 109.5, 111.3, 112.6, 113.4, 119.1, 120.2, 
120.9, 126.2, 126.5, 127.3, 127.8, 129.9, 132.5, 137.4, 139.2, 150.1, 156.2, 158.3, 
160.1, 160.4, 168.1.  MS (ES+) m/z 516.1 (M+1); HRMS (ES+) calcd for 
C30H29NO7Na (M+Na): 538.1944, found 538.1939.  IR (neat): 2860, 2800, 1730, 
1640, 1500, 1440, 1230, 920, 890, 810 cm-1. 
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Appendix 
Molecular modeling.  All protein models were built using version 1.0 Pymol 
comparative protein modeling open-source software from DeLano Scientific.  Protein 
structure homology comparisons were done using SwissModel via the ExPASy web 
server.  Initial models and sequences were adapted from two Protein Data Bank files: 
2CGE, middle and C-terminal Hsp82 domains (residues 273-677); and 2CG9, full 
length Hsp82 structure (residues 1-677) with mutant region 221-LQHMASVD-255. 
Manual editing and conformational changes were done using PyMol in Windows and 
RedHat platforms.   
Protein model structures were converted to Unix-based Sybyl molecular 
docking software version 7.1 and hybridization for individual atoms was corrected 
manually.  Hydrogen atoms were added and charges calculated within the Sybyl 
program using the Gasteiger and Marsili methods for each protein model and ligand.  
All ligand structures were built using the “Draw” functionality in Sybyl, and 
structures were minimized via 10,000 iterations to overcome maxima/minima 
limitations. One hundred docks per ligand-protein interaction were included in each 
analysis using Sybyl version 7.1 and 8.0. Connolly surfaces and electronic 
interactions were analyzed using MOLCAD.  The binding site coordinates from the 
most consistent model from each series are shown in PDB-compatible format (Model 
M1P, Table A.1; Model 3CT, Table A.2; Model EM1, Table A.3). 
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Table A.1.  Coordinates for Molecular Model M1P Binding Sites. 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
3006   N    TYR     473      -53.021  15.684   9.482  
3007   CA   TYR     473      -51.873  16.539   9.615  
3008   C    TYR     473      -51.613  16.807  11.070  
3009   O    TYR     473      -52.428  16.456  11.940  
3010   CB   TYR     473      -52.061  17.856   8.865  
3011   CG   TYR     473      -53.169  18.801   9.357  
3012   CD1  TYR    473      -52.847  19.914  10.119  
3013   CD2  TYR     473      -54.500  18.622   8.990  
3014   CE1  TYR    473      -53.808  20.811  10.544  
3015   CE2  TYR    473      -55.471  19.505   9.399  
3016   CZ   TYR    473      -55.118  20.606  10.189  
3017   OH   TYR    473      -56.084  21.495  10.619  
3018   N    ILE    474      -50.449  17.403  11.319  
3019   CA  ILE    474      -50.083  17.896  12.640  
3020   C    ILE    474      -49.410  19.269  12.509  
3021   O    ILE    474     -48.656  19.540  11.541   
3022   CB   ILE    474      -49.208  16.922  13.411  
3023   CG1  ILE    474      -48.727  17.574  14.680  
3024   CG2  ILE    474      -48.045  16.419  12.573   
3025   CD1  ILE    474     -48.444  16.564  15.800  
3026   N    THR    475      -49.729  20.147  13.468  
3027   CA  THR    475      -49.276  21.533  13.498  
3028   C    THR    475      -48.344  21.714  14.669  
3029   O    THR    475      -48.572  21.143  15.744  
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3030   CB   THR    475      -50.453  22.401  13.710  
3031   OG1  THR    475      -51.298  21.791  14.705  
3032   CG2  THR    475      -51.195  22.521  12.398  
3033   N    GLY    476      -47.285  22.487  14.479  
3034   CA   GLY    476      -46.301  22.675  15.557  
3035   C    GLY    476      -45.118  23.546  15.191  
3036   O    GLY    476      -45.010  24.007  14.067  
3037   N    GLU    477      -44.224  23.761  16.139  
3038   CA   GLU    477      -43.139  24.710  15.961  
3039   C    GLU    477      -42.303  24.511  14.696  
3040   O    GLU    477     -42.178  25.409  13.877  
3041   CB   GLU    477      -42.218  24.628  17.157  
3042   CG   GLU    477      -41.696  25.946  17.564  
3043   CD   GLU    477      -42.498  26.550  18.717  
3044   OE1  GLU    477      -42.226  26.120  19.882  
3045   OE2  GLU    477       -43.362  27.458  18.466  
3046   N    SER    478      -41.710  23.332  14.570  
3047   CA   SER    478      -40.792  23.000  13.501  
3048   C    SER    478      -40.925  21.524  13.228  
3049   O    SER    478      -41.605  20.816  13.959  
3050   CB   SER    478      -39.363  23.263  13.950  
3051   OG  SER    478      -38.932  22.260  14.854   
3052   N    LEU    479      -40.255  21.049  12.189  
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3053   CA   LEU    479      -40.220  19.627  11.903   
3054   C    LEU    479      -39.653  18.872  13.100 
3055   O    LEU    479      -40.295  17.962  13.604  
3056   CB   LEU    479      -39.400  19.371  10.644  
3057   CG   LEU   479      -39.480  18.036   9.908  
3058   CD1 LEU    479     -39.762  18.269   8.443  
3059   CD2  LEU    479      -38.197  17.308  10.067  
3060   N    LYS    480      -38.482  19.274  13.575  
3061   CA   LYS    480      -37.850  18.611  14.720   
3062   C   LYS    480      -38.796  18.388  15.892  
3063   O    LYS    480      -38.805  17.337  16.512  
3064   CB   LYS    480      -36.658  19.424  15.214  
3065   CG   LYS    480      -35.590  19.646  14.169  
3066   CD   LYS    480      -34.355  20.293  14.781  
3067   CE   LYS    480      -33.517  19.323  15.609  
3068   NZ   LYS    480      -32.264  19.981  16.066  
3069   N    ALA    481     -39.594  19.398  16.184  
3070   CA   ALA    481      -40.461  19.381  17.338  
3071   C    ALA    481      -41.648  18.440  17.112  
3072   O    ALA    481      -42.021  17.645  18.001  
3073   CB   ALA    481      -40.940  20.798  17.609  
3074   N    VAL    482      -42.199  18.527  15.902  
3075   CA   VAL    482      -43.439  17.897  15.530  
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3076   C    VAL    482     -43.349  16.347  15.403  
3077   O    VAL    482      -44.337  15.627  15.537  
3078   CB  VAL    482      -43.989  18.608  14.266  
3079   CG1  VAL    482      -43.930  17.735  13.019  
3080   CG2  VAL    482      -45.384  19.103  14.508  
3081   N    GLU    483      -42.171  15.808  15.186  
3082   CA   GLU    483      -42.073  14.356  15.113  
3083   C    GLU    483      -42.079  13.717  16.500  
3084   O    GLU    483      -42.453  12.552  16.652  
3085   CB   GLU    483      -40.824  13.941  14.349  
3086   CG   GLU    483      -40.732  14.587  12.983  
3087   CD   GLU    483      -39.330  14.542  12.387  
3088   OE1  GLU    483      -38.310  14.486  13.141  
3089   OE2  GLU    483      -39.257  14.576  11.140  
4200   N    ILE    622      -52.012   4.523  34.839  
4201   CA   ILE    622      -53.454   4.723  34.875  
4202   C    ILE    622      -54.127   3.556  35.589  
4203   O    ILE    622      -54.869   3.766  36.551  
4204   CB   ILE   622      -54.031   4.973  33.462  
4205   CG1  ILE    622     -53.854   6.431  33.083  
4206   CG2  ILE    622      -55.495   4.691  33.411  
4207   CD1  ILE    622      -52.453   6.779  32.881  
4208   N    LYS    623      -53.831   2.336  35.137   
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
4209   CA   LYS    623     -54.343   1.110  35.770  
4210   C    LYS    623     -54.309   1.203  37.292  
4211   O    LYS    623      -55.243   0.784  37.981  
4212   CB   LYS    623      -53.532  -0.105  35.331   
4213   CG   LYS    623      -53.595  -0.422  33.844 
4214   CD   LYS    623      -52.826  -1.702  33.529  
4215   CE   LYS    623      -52.517  -1.865  32.033  
4216   NZ   LYS    623      -53.696  -2.304  31.207  
4217   N    GLU    624      -53.216   1.780  37.780  
4218   CA   GLU    624      -52.960   1.989  39.190  
4219   C    GLU    624      -53.890   3.021  39.838  
4220   O    GLU    624      -54.405   2.798  40.941  
4221   CB  GLU    624      -51.495   2.398  39.381  
4222   CG  GLU    624      -51.125   2.745  40.819  
4223   CD   GLU    624      -51.568   1.684  41.800  
4224   OE1  GLU    624      -51.010   0.576  41.746  
4225   OE2  GLU    624      -52.481   1.950  42.609  
4226   N    LEU    625      -54.086   4.151  39.171  
4227   CA   LEU    625      -54.981   5.168  39.693  
4228   C    LEU    625      -56.418   4.643  39.803  
4229   O    LEU    625      -57.142   4.970  40.759  
4230   CB   LEU    625      -54.944   6.416  38.814  
4231   CG   LEU    625      -53.837   7.440  39.004  
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
4232   CD1  LEU    625      -53.787   8.291  37.771  
4233   CD2  LEU    625      -54.083   8.288  40.230  
4234   N    LYS    626      -56.821   3.826  38.826  
4235   CA   LYS    626      -58.129   3.175  38.859  
4236   C    LYS    626      -58.221   2.380  40.136   
4237   O    LYS    626      -59.209   2.468  40.851  
4238   CB   LYS    626      -58.320   2.292  37.624  
4239   CG   LYS    626      -59.685   1.630  37.539  
4240   CD   LYS    626     -59.805   0.770  36.291   
4241   CE   LYS    626      -61.171   0.108  36.207  
4242   NZ   LYS    626      -61.388  -0.862  37.316  
4243   N    LYS    627      -57.160   1.638  40.436  
4244   CA   LYS    627     -57.138   0.762  41.607  
4245   C    LYS    627      -57.431   1.518  42.889  
4246   O    LYS    627      -58.268   1.086  43.695  
4247   CB   LYS    627      -55.816  -0.013  41.721  
4248   CG   LYS    627      -55.499  -0.923  40.530  
4249   CD   LYS    627      -56.594  -1.962  40.274  
4250   CE   LYS    627      -57.662  -1.458  39.286  
4251   NZ   LYS    627     -58.949  -2.219  39.385  
4252   N    ARG    628      -56.769   2.661  43.056  
4253   CA   ARG    628      -56.916   3.433  44.277  
4254   C    ARG    628      -58.316   4.019  44.383 
(continued) 
 - 80 -
Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
4255   O    ARG    628      -58.851   4.144  45.477  
4256   CB   ARG    628      -55.843   4.504  44.373  
4257   CG   ARG    628      -54.451   3.941  44.303  
4258   CD   ARG    628      -53.531   4.668  45.239  
4259   NE   ARG    628      -52.173   4.138  45.170  
4260   CZ   ARG   628      -51.122   4.676  45.785  
4261   NH1  ARG    628      -51.275   5.775  46.523   
4262   NH2  ARG    628     -49.919   4.115  45.660  
4263   N    VAL    629      -58.905   4.336  43.232  
4264   CA   VAL    629      -60.275   4.863  43.140  
4265   C    VAL    629      -61.315   3.790  43.461  
4266   O    VAL    629      -62.265   4.029  44.212  
4267   CB   VAL    629      -60.531   5.514  41.732  
4268   CG1  VAL    629      -62.009   5.500  41.333  
4269   CG2  VAL    629      -59.966   6.927  41.702  
4270   N    ASP    630      -61.109   2.609  42.887  
4271   CA   ASP    630      -61.945   1.433  43.139  
4272   C    ASP    630      -61.719   0.927  44.556  
4273   O    ASP    630      -62.097  -0.196  44.886  
4274   CB   ASP    630      -61.624   0.320  42.123  
4275   CG   ASP    630      -61.970   0.711  40.679  
4276   OD1  ASP    630      -62.985   1.414  40.477  
4277   OD2  ASP   630      -61.240   0.310  39.740   
(continued) 
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Table A.1.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
4278   N    GLU   631      -61.086   1.768  45.375  
4279    CA   GLU   631      -60.759   1.459  46.765  
4280   C    GLU   631      -60.936   2.691  47.643  
4281   O    GLU   631      -60.097   2.987  48.494  
4282   CB   GLU   631      -59.330   0.917  46.868  
4283   CG   GLU   631      -59.206  -0.552  46.459  
4284   CD   GLU   631      -57.765  -1.012  46.253  
4285   OE1  GLU   631      -56.921  -0.205  45.796  
4286   OE2  GLU   631      -57.482  -2.198  46.536  
4287   N    GLY   632      -62.034   3.410  47.409  
4288   CA   GLY   632      -62.415   4.585  48.196  
4289   C    GLY   632      -61.477   5.775  48.098  
4290   O    GLY   632      -61.826   6.884  48.521  
4291   N    GLY   633      -60.284   5.546  47.543  
4292   CA   GLY   633      -59.253   6.586  47.398  
4293   C    GLY   633      -59.582   7.669  46.380  
4294   O    GLY   633      -58.694   8.141  45.662   
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Table A.2  Coordinates for Molecular Model 3CT Binding Sites. 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3106   N  GLU   376   -78.639 -69.920  43.803   
3107   CA   GLU    376    -78.719 -68.446  43.838   
3108    C   GLU    376  -78.924 -67.876  42.427   
3109   O    GLU    376      -79.823 -67.070  42.211   
3110   CB   GLU    376      -77.417 -67.872  44.402   
3111   CG   GLU    376      -77.195 -68.202  45.880  
3112   CD   GLU    376      -77.928 -67.248  46.829  
3113   OE1  GLU    376      -79.147 -67.025  46.646  
3114   OE2  GLU    376      -77.240 -66.748  47.742   
3115   N    THR    377      -78.207 -68.460  41.466   
3116   CA   THR    377      -78.322 -68.082  40.043   
3117   C    THR    377      -79.729 -68.369  39.509   
3118   O    THR    377      -80.288 -67.540  38.784   
3119   CB   THR    377      -77.275 -68.820  39.191   
3120   OG1  THR    377      -75.978 -68.377  39.590   
3121   CG2  THR    377      -77.448 -68.609  37.680   
3122   N    ALA    378     -80.256 -69.541  39.832   
3123   CA   ALA    378      -81.603 -69.954  39.400   
3124   C    ALA    378      -82.650 -68.927  39.843   
3125   O    ALA    378      -83.371 -68.419  39.001  
3126   CB   ALA    378      -81.941 -71.325  39.976   
3127   N    LEU    379      -82.525 -68.463  41.091   
3128   CA   LEU    379      -83.348 -67.369  41.631   
(continued) 
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Table A.2.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3129   C    LEU    379      -83.310 -66.132  40.729   
3130   O   LEU    379      -84.335 -65.710  40.245   
3131   CB   LEU    379      -82.860 -66.960  43.021   
3132   CG   LEU    379      -83.065 -68.054  44.066   
3133   CD1  LEU    379      -82.329 -67.670  45.347   
3134   CD2  LEU    379     -84.553 -68.224  44.381   
3135   N    LEU    380      -82.103 -65.752  40.297   
3136   CA   LEU    380      -81.967 -64.638  39.346   
3137   C    LEU    380      -82.613 -64.914  37.994   
3138   O    LEU    380      -83.586 -64.256  37.625   
3139   CB   LEU    380      -80.511 -64.208  39.130   
3140   CG   LEU    380     -79.935 -63.340  40.256  
3141   CD1  LEU    380      -80.938 -62.309  40.794   
3142   CD2  LEU    380     -79.311 -64.190  41.361   
3143   N    SER    381      -82.151 -65.988  37.369   
3144   CA   SER    381      -82.635 -66.415  36.043   
3145   C    SER    381    -84.162 -66.589  36.016   
3146   O    SER    381      -84.834 -66.087  35.113   
3147   CB   SER    381     -81.971 -67.738  35.658   
3148   OG   SER    381      -82.454 -68.150  34.378   
3149   N    SER    382      -84.699 -67.172  37.075   
3150   CA   SER    382      -86.141 -67.456  37.216   
3151   C    SER    382      -86.929 -66.271  37.803   
3152   O    SER    382      -88.083 -66.429  38.203   
(continued) 
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Table A.2.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3153   CB   SER    382      -86.340 -68.715  38.071   
3154   OG   SER    382      -85.679 -69.829  37.454 
3155   N    GLY    383      -86.314 -65.081  37.760   
3156   CA   GLY    383      -86.935 -63.819  38.211   
3157   C    GLY    383      -87.280 -63.813  39.705   
3158   O    GLY    383      -88.451 -63.682  40.096   
3159   N    PHE    384      -86.263 -63.929  40.516   
3160   CA   PHE    384      -86.309 -63.821  41.987   
3161   C    PHE    384      -85.138 -62.971  42.469   
3162   O    PHE    384      -84.107 -62.857  41.794   
3163   CB   PHE    384      -86.181 -65.190  42.668  
3164   CG   PHE    384      -87.471 -66.002  42.698  
3165   CD1  PHE    384      -88.341 -65.820  43.765   
3166   CD2  PHE    384      -87.707 -67.006  41.764   
3167   CE1  PHE    384      -89.449 -66.639  43.902   
3168   CE2  PHE    384      -88.816 -67.829  41.904   
3169   CZ   PHE    384      -89.688 -67.640  42.971   
3170   N    SER    385      -85.350 -62.292  43.583   
3171   CA   SER    385      -84.225 -61.746  44.361   
3172   C    SER    385      -83.621 -62.913  45.155   
3173   O    SER    385      -84.311 -63.888  45.487   
3174   CB   SER    385      -84.668 -60.625  45.307   
3175   OG   SER    385      -85.429 -61.168  46.382  
(continued)  
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Table A.2.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3176   N    LEU    386      -82.340 -62.832  45.425   
3177   CA   LEU    386      -81.602 -63.927  46.080   
3178   C    LEU    386      -81.621 -63.793  47.612   
3179   O    LEU    386      -82.443 -63.090  48.197   
3180   CB   LEU    386      -80.180 -64.013  45.503   
3181   CG   LEU    386      -79.420 -62.686  45.606   
3182   CD1  LEU    386      -77.925 -62.957  45.626   
3183   CD2  LEU    386      -79.719 -61.791  44.402   
3184   N    GLU    387      -80.647 -64.445  48.237   
3185   CA   GLU    387      -80.514 -64.481  49.696   
3186   C    GLU    387      -79.217 -63.858  50.166 
3187   O    GLU    387      -78.197 -64.535  50.302   
3188   CB   GLU    387     -80.615 -65.928  50.158   
3189   CG   GLU    387      -82.068 -66.321  49.925   
3190   CD   GLU    387      -83.044 -65.817  50.987   
3191   OE1  GLU    387      -82.643 -64.963  51.811   
3192   OE2  GLU    387      -84.183 -66.323  50.956   
3193   N    ASP    388      -79.315 -62.556  50.416   
3194   CA   ASP    388      -78.237 -61.796  51.071   
3195   C    ASP    388      -77.016 -61.568  50.161   
3196   O    ASP    388      -76.673 -62.428  49.340   
3197   CB   ASP    388      -77.797 -62.474  52.385   
3198   CG   ASP    388      -78.980 -62.628  53.340  
(continued)  
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Table A.2.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
3199   OD1  ASP    388      -79.510 -61.567  53.731   
3200   OD2  ASP    388      -79.334 -63.792  53.622   
3201   N    PRO    389     -76.359 -60.420  50.352   
3202   CA   PRO    389      -75.159 -60.018  49.600   
3203   C    PRO    389      -74.017 -60.982  49.935   
3204   O    PRO    389      -73.805 -61.918  49.193  
3205   CB   PRO    389      -74.898 -58.576  50.041   
3206   CG   PRO    389      -75.392 -58.551  51.489   
3207   CD   PRO    389      -76.639 -59.426  51.417   
3208   N    GLN    390      -73.332 -60.720  51.062   
3209   CA   GLN    390      -72.272 -61.544  51.674   
3210   C    GLN    390      -72.050 -62.910  51.014   
3211   O    GLN    390     -71.340 -62.963  49.996   
3212   CB   GLN    390      -72.541 -61.681  53.186   
3213   CG   GLN    390      -73.932 -62.259  53.490   
3214   CD   GLN    390      -74.107 -62.554  54.964   
3215   OE1  GLN    390      -74.207 -61.627  55.748   
3216   NE2  GLN    390      -74.171 -63.815  55.342   
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Table A.3.  Coordinates for Molecular Model EM1 Binding Sites. 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
2286   N    LYS    273       23.858  10.667  34.892   
2287   CA   LYS    273       23.451   9.298  34.532  
2288   C    LYS    273       23.720   8.313  35.678  
2289   O    LYS    273       22.833   7.544  36.062   
2290   CB   LYS    273       24.218   8.847  33.284  
2291   CG   LYS    273       23.796   7.454  32.805  
2292   CD   LYS    273       22.338   7.447  32.346   
2293   CE   LYS    273       21.873   6.068  31.879   
2294   NZ   LYS    273       21.867   5.100  32.983   
2295   N    THR    274       24.891   8.454  36.287   
2296   CA   THR    274       25.277   7.638  37.460  
2297   C    THR    274       24.360   7.880  38.662  
2298   O    THR    274      23.891   6.907  39.270  
2299   CB   THR    274       26.718   7.905  37.897   
2300   OG1  THR    274       26.836   9.270  38.288  
2301   CG2  THR    274       27.725   7.539  36.801  
2302   N    LYS    275       23.968   9.121  38.888  
2303   CA   LYS    275       23.034   9.499  39.967  
2304   C    LYS    275       21.685   8.772  39.830  
2305   O    LYS    275       21.047   8.440  40.824  
2306   CB   LYS    275       22.769  11.004  39.981  
2307   CG   LYS    275       24.005  11.835  40.329  
2308   CD   LYS    275       23.672  13.331  40.388  
2309   CE   LYS    275       22.683  13.680  41.507   
(continued) 
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Table A.3.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
2310   NZ   LYS    275       23.245  13.403  42.838   
2311   N    PHE    276       21.336   8.427  38.592  
2312   CA   PHE    276       20.010   7.878  38.270  
2313   C    PHE    276       20.056   6.363  38.208  
2314   O    PHE    276       19.010   5.729  38.224  
2315   CB   PHE    276       19.517   8.404  36.920  
2316   CG   PHE    276      19.225   9.904  36.917  
2317   CD1  PHE    276       19.959  10.814  37.675  
2318   CD2  PHE    276       18.166  10.383  36.169  
2319   CE1  PHE    276       19.680  12.156  37.708  
2320   CE2  PHE    276       17.878  11.731  36.212  
2321   CZ   PHE    276       18.626  12.633  36.960  
2322   N    GLU    277       21.264   5.804  38.207  
2323   CA   GLU    277       21.494   4.359  38.062  
2324   C    GLU    277       20.568   3.526  38.955  
2325   O    GLU    277       19.810   2.702  38.456  
2326   CB   GLU    277       22.946   4.049  38.422  
2327   CG   GLU    277       23.517   2.941  37.536  
2328   CD   GLU    277      23.865   3.446  36.134  
2329   OE1  GLU    277       22.972   4.031  35.480  
2330   OE2  GLU    277       25.022   3.214  35.732  
2331   N    ASN    278       20.528   3.873  40.244   
(continued) 
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Table A.3.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
2332   CA   ASN    278       19.648   3.192  41.203  
2333   C    ASN    278       18.161   3.334  40.892  
2334   O    ASN    278       17.407   2.461  41.251   
2335   CB   ASN    278       19.906   3.643  42.639  
2336   CG   ASN    278       21.234   3.087  43.150  
2337   OD1  ASN    278       22.121   3.821  43.551  
2338   ND2  ASN    278       21.391   1.778  43.080  
2470   N    VAL    295       16.630   3.472  30.495  
2471   CA   VAL    295       17.796   4.364  30.372  
2472   C    VAL    295       17.397   5.827  30.597  
2473   O    VAL    295      16.229   6.202  30.452  
2474   CB   VAL    295       18.510   4.171  29.014  
2475   CG1  VAL    295       18.929   2.715  28.777  
2476   CG2  VAL    295       17.687   4.684  27.826  
2477   N    VAL    296       18.405   6.645  30.829  
2478   CA   VAL    296       18.253   8.109  30.887  
2479   C    VAL    296       18.594   8.654  29.496  
2480   O    VAL    296       19.645   8.340  28.937  
2481   CB   VAL    296       19.209   8.670  31.947  
2482   CG1  VAL    296       19.323   10.194 31.911  
2483   CG2  VAL    296       18.790   8.223  33.346  
2484   N    SER    297       17.719   9.513  29.000  
2485   CA   SER    297       17.949   10.153 27.699 
(continued) 
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Table A.3.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
2486   C    SER    297       17.958   11.674 27.820  
2487   O    SER    297       17.205   12.277 28.596  
2488   CB   SER    297       16.881   9.690  26.704  
2489   OG   SER    297       17.208   10.156 25.392  
2537   N    PRO    304        8.162    13.094 30.377  
2538   CA   PRO    304        8.698    12.182 31.406  
2539   C    PRO    304        9.588    11.081 30.855  
2540   O    PRO    304       10.794   10.987 31.129  
2541   CB   PRO    304        7.466    11.561 32.081  
2542   CG   PRO    304        6.228    12.209 31.457  
2543   CD   PRO    304        6.706    13.209 30.403  
2544   N    CYS    305        8.936    10.303 30.027  
2545   CA   CYS    305        9.468    9.068  29.472  
2546   C    CYS    305        9.019    8.919  28.024  
2547   O    CYS    305        8.109    9.622  27.553  
2548   CB   CYS    305        8.957    7.902  30.323  
2549   SG   CYS    305        7.133    7.789  30.344  
2550   N    CYS    306        9.670    8.002  27.352  
2551   CA   CYS    306        9.318    7.592  25.982  
2552   C    CYS    306        9.938    6.229  25.702  
2553   O    CYS    306       10.729   5.714  26.507  
2554   CB   CYS    306        9.811    8.625  24.960  
2555   SG   CYS    306       11.621   8.598  24.748  
(continued) 
 - 91 -
Table A.3.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
5832   N    ARG    703       -1.844   24.996 32.143  
5833   CA   ARG    703      -2.750   24.300 31.219  
5834   C    ARG    703       -2.050   23.983 29.886  
5835   O    ARG    703       -2.664   23.654 28.877  
5836   CB   ARG    703       -3.939   25.223 30.966  
5837   CG   ARG    703       -4.816   25.383 32.208   
5838   CD   ARG    703       -6.076   26.174 31.866   
5839   NE   ARG    703       -5.741   27.548 31.443  
5840   CZ   ARG    703       -6.612   28.450 30.991  
5841   NH1  ARG    703       -7.900   28.152 30.870  
5842   NH2  ARG    703       -6.204   29.674 30.684  
5843   N    LEU    704       -0.725   24.100 29.906  
5844   CA   LEU    704        0.080    23.874 28.713  
5845   C    LEU    704        1.305    22.996 29.046  
5846   O    LEU    704        2.035    23.191 30.018  
5847   CB   LEU    704        0.220    25.274 28.083  
5848   CG   LEU    704        1.113    25.342 26.848  
5849   CD1  LEU    704        0.665    24.447 25.702  
5850   CD2  LEU    704        1.509    26.786 26.499  
5851   N    VAL    705        1.297    21.827 28.427  
5852   CA   VAL    705        2.307    20.791 28.717  
5853   C    VAL    705        3.261    20.612 27.536  
5854   O    VAL    705        2.842    20.595 26.376  
(continued) 
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Table A.3.  (continued) 
ATOM#  ATOM  AMINO ACID  RESIDUE#  COORDINATES 
 
5855   CB   VAL    705        1.606    19.472 29.093  
5856   CG1  VAL    705        0.775    18.926 27.937  
5857   CG2  VAL    705        2.584    18.395 29.568  
5858   N    THR    706        4.523    20.397 27.886  
5859   CA   THR    706        5.594    20.003 26.941  
5860   C    THR    706        5.557    20.773 25.608  
5861   O    THR    706        5.603    20.206 24.525  
5862   CB   THR    706        5.576    18.488 26.672  
5863   OG1  THR    706        4.305    18.102 26.134  
5864   CG2  THR    706        5.897    17.690 27.940  
5865    N    SER    707        5.324    22.075 25.726  
5866   CA   SER    707        5.304    22.948 24.542  
5867   C    SER    707        5.676    24.347 25.019  
5868   O    SER    707        5.139    24.780 25.998  
5869   CB   SER    707        3.919    22.980 23.889  
5870   OG   SER    707        3.988    23.768 22.698  
5871   N    PRO    708        6.615    25.036 24.382  
5872   CA   PRO    708        7.100    26.349 24.849  
5873   C    PRO    708        5.992    27.328 25.202  
5874   O    PRO    708        5.812    27.759 26.351  
5875   CB   PRO    708        7.935    26.911 23.688  
5876   CG   PRO    708        7.972    25.844 22.593  
5877   CD   PRO    708        7.155    24.646 23.082   
 
